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OVERVIEW 
  
 Uterine leiomyoma (fibroids), benign tumors of the uterus, are the most common female 
pelvic tumor (1). The majority of U.S. women have at least one uterine fibroid by the age of 
menopause (2). Symptoms of fibroids include abnormal bleeding during menstruation, increased 
urinary frequency, and pelvic pressure (3, 4). Fibroids are a major cause of hysterectomies (5), 
primarily to manage symptoms and costs in the U.S. are up to $34.4 billion (2010 dollars) 
annually in healthcare, treatment, and work loss costs (6).  
 
Fibroids are highly heterogeneous, with some women developing a single small fibroid 
while other women develop multiple and/or large fibroids. African American (AA) women for 
example have an approximately two- to three-fold higher risk of fibroids when compared to 
European American (EA) women (7) and also have more numerous and larger fibroids (2). 
Additionally, AAs are two times more likely than EAs to receive surgical treatments for fibroids 
such as a hysterectomy (8). Unfortunately, most research on fibroids to date has not evaluated 
risk factors for specific fibroid characteristics. The purpose of this thesis is to provide a deeper 
understanding on both epidemiology and genetic risk factors of fibroid characteristics, fibroid 
number (single vs. multiple), volume of largest fibroid, and largest dimension of all fibroid 
measurements. 
 
 Chapter I provides a broad overview of the epidemiology on uterine fibroids and fibroid 
characteristics. This encompasses the morphology, incidence, and progression of fibroids. 
Detailed descriptions of symptoms associated with fibroids and subsequent treatments for 
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fibroids are given. Numerous risk factors for fibroids and fibroid characteristics are described 
including age (2), menarche (9), body mass index (BMI) (kg/m
2
) (10), race (11-14), parity (15, 
16), and type 2 diabetes (17, 18). Finally, fibroids are heritable and have a genetic component 
(19, 20). Current advances, understandings, and limitations of fibroid genetic research are listed. 
 
Chapter II focuses on identifying physical and clinical features of women that are 
associated with fibroid size and number. We accomplished this by using a validated phenotyping 
algorithm (21) to identify 2,302 fibroid cases from the Synthetic Derivative (22). The Synthetic 
Derivative consists of de-identified electronic health records (EHRs) of patients who visit the 
Vanderbilt University Medical Center (VUMC) network (22). After abstracting fibroid 
characteristics and candidate risk factors using a combination of manual review and phenotyping 
algorithms, we performed regression analyses using exposures age, BMI, race (black or white), 
type 2 diabetes, and number of living children (proxy to parity). We assessed for potential effect 
measure modification by race and both age and BMI using a likelihood ratio test.  
 
 Chapter III estimates the heritability of fibroids using genome-wide association study 
(GWAS) data. In this chapter, we estimate and characterize the heritability of image-confirmed 
fibroid cases and controls from EA women using GWAS data. Our study consisted of women 
from BioVU. We estimated the genetic variance explained by all single nucleotide 
polymorphisms (SNPs) using Genome-wide Complex Trait Analysis (GCTA) (23) for fibroid 
risk and size on imputed data. The final models were adjusted for age, BMI, and five PCs. We 
also characterized the heritability of fibroids by partitioning the genetic variance into 
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chromosomes and into genic and intergenic regions. Lastly, we characterized fibroid heritability 
after excluding genomic regions previously implicated with fibroid risk. 
 
 Chapter IV focuses on the effects that African ancestry has on fibroid number and size 
(24). Using 609 AAs with image- or surgery confirmed fibroids from BioVU and the Coronary 
Artery Risk Development in Young Adults (CARDIA) study, we estimated local and global 
African and European ancestry from GWAS data. Next, we performed linear and logistic 
regression on global and local ancestry for each fibroid characteristics for BioVU and CARDIA. 
Meta-analyses comparing global or local ancestry across CARDIA and BioVU AAs were then 
performed for each outcome. Suggestive peaks were further evaluated for single SNP 
associations in separate analyses by characteristics. Lastly, we performed local ancestry analysis 
adjusting for the most significant single SNP association within the admixture mapping peak 
regions in order to identify any genetic/imputed SNPs that explain the ancestry peaks. 
 
 Chapter V summarizes Chapters II-IV, highlighting main strengths and limitations of our 
results. We review how our findings contribute to epidemiologic and genetic risk factors for 
fibroid characteristics among AA and EA women. In addition, our research gives insight for 
future directions for genetic studies on fibroid heritability. Lastly, we discuss future directions 
involving characteristics and heritability of fibroids. 
  
4 
 
CHAPTER 1  
 
INTRODUCTION TO UTERINE FIBROIDS AND FIBROID CHARACTERISTICS 
 
Fibroid Morphology 
 
 Uterine fibroids, or leiomyomas, are the most common female pelvic tumor (1), are 
located in the myometrium of the uterus (25, 26), and very rarely become malignant (26). 
Fibroids are composed of smooth muscle fibers and fibrous connective tissue and are roundish in 
shape (26). Tumors can range in size from a few millimeters to many centimeters and can form 
in any location within the uterus (26). Fibroid subtypes are denoted by location within the uterus: 
submucosal fibroids are located along the inside wall, intramural fibroids are located within the 
wall, subserosal are located on the outside wall, and pedunculated fibroids are attached to the 
uterine wall via a stalk (25). Fibroids are monoclonal in origin, likely rising from a single cell 
(27). In a study by Linder and Gartler (1965), the authors ascertained the expression of X-linked 
glucose-6-phosphate dehydrogenase (G6PD) of 86 normal myometrium tissue samples and 27 
fibroids from five women who were heterozygous for the G6PD loci (A and B). The authors 
found that nearly all the normal myometrial samples expressed both A and B while all the fibroid 
tissues expressed exclusively G6PD variant A or B (27).  In addition to fibroids being 
monoclonal in origin, fibroids are a heterogeneous disease where some women will develop a 
small/single fibroid, and other women will large/numerous fibroids. 
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Fibroid Epidemiology 
 Fibroid Incidence and Prevalence 
 
 Prevalence estimates from pathology reports place fibroid prevalence between 20 to 77% 
(1). In 1933, Graves published the first prevalence estimate for fibroid presence by examining 
autopsies of women over 35 years old and observed that 20% of women had fibroids (1). In 
1990, Cramer and Patel observed that 77% women have fibroids after examining 100 
consecutive hysterectomy specimens from serial sectioning at two mm intervals (1, 28). More 
recently in 2003, Baird et al. assessed the cumulative incidence of fibroids via ultrasounds using 
1,364 black and white US women aged 35 to 49 years who were part of an urban health plan (2). 
Baird et al. found that the cumulative incidence of fibroids was above 80% for black women and 
approximately 70% for white women by age 49 (2). In addition, the authors estimated the 
prevalence of clinically relevant fibroids if a women had at least one submucosal fibroid, a large 
uterus (≥10 centimeters [cm] in length), or at least one large fibroid (≥4 cm in largest dimension) 
(2). The authors found that approximately 50% of black women and 35% of white women had a 
clinically relevant fibroid by age 49 (2). Interestingly, the authors noted that 51% of women 
without a previous diagnosis of fibroids observed a fibroid during ultrasound assessment (2), 
noting the need for imaging studies on fibroid risk. Lastly, the authors also found that black 
women were more likely to have multiple fibroids and larger newly detected fibroids than white 
women (2). 
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 Public Health Impact of Fibroids 
 
 Approximately 25% of fibroids are symptomatic with symptoms depending on location, 
number, and size of the leiomyomas (25, 29). Symptoms of fibroids include the following: 
 menorrhagia - prolonged and heavy bleeding during menstruation 
 anemia - lack of red blood cells 
 pain  
 pelvic pressure  
 increased urinary frequency  
 constipation  
 pregnancy complication  
 premature labor  
 infertility (25)  
Symptoms are connected with fibroid location, number, and size (25, 29). For example, 
submucosal fibroids are accompanied with menorrhagia while large fibroids are accompanied 
with pelvic pressure of the lower abdomen (25). In addition, large fibroids have previously been 
associated with preterm premature rupture of membranes, while multiple fibroids have 
previously been associated with cesarean delivery and preterm birth (30). 
 
 Fibroids costs the US approximately 5.9 to 34.4 billion dollars annually for treatment, 
healthcare, and lost work costs (6), largely to manage symptoms. Surgical treatment options 
include myomectomies and hysterectomies (25, 31, 32). Myomectomies include removing the 
fibroid(s) while preserving the uterus, and hysterectomies involve removal of the fibroids with 
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the uterus, thus removing the chance of fibroid recurrence. In addition, fibroids are most 
common indication of hysterectomy in the US (5). Less invasive procedures include uterine 
artery embolization (UAE) and magnetic resonance-guided focused ultrasound (MRgFUS) (14, 
31, 32).  The UAE procedure includes injecting occluding agents into arteries of the uterus (32) 
to reduce or stop blood flow to a fibroid, thus reducing its size. The MRgFUS procedure uses 
focused ultrasounds to selectively cause thermal damage and necrosis of fibroid tissue (33). 
Lastly, fibroids, being composed of uterine tissue, have a hormonal component (14), and there 
are short-tern hormonal treatment options. Among the most used drugs, gonadotropin-releasing 
hormone (GnRH) agonists cause a temporary menopause among premenopausal women, thus 
reducing the size of fibroids and causing amenorrhoea (25). The GnRH agonists, however, are 
only approved for temporary use because of long-term side effects, and upon GnRH agonist 
discontinuation, bleeding symptoms and fibroid size returns to pretreatment levels (25).  
 
 Fibroid Risk Factors 
 
 Selected studies on exposures of fibroid risk are shown in Table 1.1. 
 
  Age 
 
 Cumulative incidence and clinically relevant prevalence of fibroids increases with age 
during reproductive years (2). Since fibroids have a hormonal component responding to estrogen 
and progesterone, fibroids have not been documented in prepubescent girls (25) likely forming 
after menarche. Prevalence of fibroids needing surgery decreases after menopause (34). In 1990, 
Cramer and Patel (1990) performed serial sectioning of uterine tissue from 100 consecutive 
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hysterectomies and found that postmenopausal women were found to have smaller and fewer 
fibroids compared to premenopausal women (28).  
 
  Menarche 
 
 Age at menarche has been inversely associated with fibroid risk (35). Having an early age 
at menarche could lead to an increase in menstrual cycles (35). The increase in uterine cell 
divisions from menstruating could lead to a higher mutation load in genes controlling 
myometrial proliferation (35) leading to an increase in fibroid risk. Using a cohort of 95,061 
women from the Nurses’ Health Study II cohort, Marshall et al. found that compared to women 
who were 12 years at menarche, those who were ≤10 years old at menarche had a higher risk of 
fibroids (35). In addition, the authors found that women who were ≥16 years at menarche had a 
decreased fibroid risk (35). In another study by Velez Edwards et al. (2013), the authors 
performed association analyses between age at menarche and fibroid risk, number, size, and 
location using 540 fibroid cases and 4,483 control from the Right From the Start study, a 
community-based pregnancy cohort (9). Velez Edwards et al. observed that 1-year increase in 
age at menarche was inversely associated with fibroid risk (9). Furthermore, the authors found 
that early age at menarche was associated with increased fibroid number and size (9).  
 
  BMI 
 
 Increasing BMI and obesity have been associated with fibroid risk (34). Obesity 
decreases the metabolism of estradiol to inactive metabolites, which could produce a 
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hyperestrogenic state (34, 36). This increase in estrogen could lead to an increased fibroid risk or 
to more numerous and larger fibroids since fibroids have a hormonal component responding to 
estrogen (25). Using women from the Oxford Family Planning Association study, Ross et al. 
(1986) observed that women had a 21% increase risk for fibroids for every 10 kg increase using 
1,070 women (535 cases) (37). Similar trends were observed when using BMI instead of weight 
(37). In another study, Marshal et al. (1998) performed association analyses between BMI and 
fibroid risk using 94,095 premenopausal from the Nurses’ Health Study II (38). The authors 
observed that adult BMI is associated with increased fibroid risk (38). The associations between 
BMI and fibroid characteristics are less known. In one study, Dandolu et al. (2010) compared 
BMI with fibroid risk and largest dimension using 873 women (533 cases) who had 
hysterectomies at the Temple University Hospital between 1995-2002 (10). Fibroid size was 
dichotomized to larger or smaller than 2 cm (10). The authors found that while BMI positively 
correlated with fibroid risk (p <0.0001), BMI was not correlated with fibroid largest dimension 
(p = 0.11) (10).  
 
  Race 
 
 Black race has been associated with fibroids in many studies (2, 7, 25). In 1997, Marshall 
et al. estimated the incidence rate of fibroids using 95,061 black and white women from the 
Nurses’ Health Study II (7). The authors observed that the incidence of fibroids was two- to 
three-fold higher among black women compared to white women (7). In 2003, Baird et al. 
assessed the cumulative incidence and clinically relevant prevalence of fibroids by ultrasounds 
using 1,364 black and white women from ages 35 to 49 years old who were part of an urban 
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health plan (2). Baird et al. observed that the cumulative incidence of fibroids was higher at 
every examined age for black women compared to white women (2). In addition, the authors 
estimated the prevalence of clinically relevant fibroids if a women had at least one submucosal 
fibroid, a large uterus (≥10 cm in length), or at least one large fibroid (≥4 cm in largest 
dimension) (2). The authors again observed that black women had a higher prevalence of 
clinically relevant fibroids at every age compared to white women (2). Furthermore, authors also 
found that black women were more likely to have multiple fibroids and larger newly detected 
fibroids than white women (2).  
 
 In another study by Moorman et al., the authors examined differences in fibroid 
characteristics and their risk factors between black and white women (N=360) undergoing 
hysterectomy from the Prospective Research on Ovarian Function study. All fibroid 
characteristic information was abstracted from pathology and operative notes (39). The authors 
found that black women on average had larger and more numerous fibroids than white women 
(39). Likely culminating from the higher incidence of fibroids and from the larger and more 
numerous fibroids among black women, Wilcox et al. (1994) observed that black women had a 
two-fold higher risk of having a hysterectomy because of fibroids. The authors used data 
obtained from the National Hospital Discharge Survey (8). 
 
  Parity 
 
 Parity, or the number of times a women gives birth, has been inversely associated with 
fibroids (34), where nulliparity has been associated with increased risk (40). Interestingly, 
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pregnancies that stop before viability have not been implicated with decreasing fibroid risk (40). 
In 1988, Parazzini et al. recruited 275 fibroid cases and 722 controls from women in the greater 
Milan area and observed that parous women were 40% less likely to have fibroids compared to 
nulliparous women (41). In another study, Ross et al. (1986) observed that fibroid risk decreased 
with each term pregnancy using 1,070 women (535 cases) from the Oxford Family Planning 
Association study (37). The authors observed that women with five term pregnancies had 
an approximately four-fold reduction in fibroid risk compared to women with zero term 
pregnancies (37). The relationship between parity and fibroid characteristics such as fibroid 
number and size remain less clear. 
 
  Type 2 Diabetes 
 
 There have been a few studies evaluating the association between diabetes and fibroid 
risk where having diabetes is associated with a decreased fibroid risk (17, 18, 42). In 2007, Wise 
et al. examined the association between diabetes with and without medication use and uterine 
fibroids using 23,571 AA women from the Black Women’s Health Study, a prospective cohort 
(17). Wise et al. observed that diabetes was inversely associated with fibroids for women using 
medication (incidence rate ratio [IRR]: 0.77; 95% confidence interval [CI]: 0.60, 0.98) but was 
not associated with fibroids for women not using medication (IRR: 0.91; 95% CI: 0.64, 1.28) 
(17). In another study in 2017, Velez Edwards et al. performed association analyses between 
diabetes with and without medication use and fibroids using black and white women from the 
Synthetic Derivative, a database of de-identified EHRs of patients from the VUMC (18). Velez 
Edwards et al. observed that diabetes was inversely associated among white women (adjusted 
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odds ratio [aOR]: 0.50; 95% CI: 0.35, 0.72) and not among black women (aOR: 0.76; 95% CI: 
0.50, 1.17) (18). When stratifying women by type of diabetes medication usage, Velez Edwards 
observed that diabetes was inversely associated with fibroids for white women on insulin only 
(aOR: 0.42; 95% CI: 0.26, 0.68) compared to other drugs Metformin and Thiazolidinedione (18). 
There was a trend towards an inverse association between diabetes and fibroids for black women 
on insulin, but this association was not significant (aOR: 0.60; 95% CI: 0.36, 1.01) (18). While 
there is little known about the association between diabetes and fibroid size or number, there has 
been one study examining associations between hormones (insulin-like growth factor-I [IGF-I] 
and insulin) and proteins (protein binding 3 [BP3]) related to diabetes and fibroid size (42). In a 
cross-sectional study by Baird et al. (2009), the authors used 988 women (630 cases) who had 
ultrasounds from the National Institute of Environmental Health Sciences Uterine Fibroid Study 
and found that having a small (<2 cm) and medium (≥2 to <4 cm) sized fibroid was inversely 
associated with increased levels of insulin-like growth factor-I in white women and having a 
large fibroid (≥4 cm) was inversely associated with insulin levels, especially in black women 
(42). Baird et al. found no association between BP3 and fibroid size (42).  
 
Genetic Contributions to Uterine Fibroids 
 Heritability Studies 
 
 Fibroids are heritable with two twin studies estimating fibroid heritability to be between 
26 to 69% among women of European ancestry (19, 20). In the first twin study, Snieder et al. 
(1998) used data on 98 monozygotic (MZ) and 125 dizygotic (DZ) twin pairs from the United 
Kingdom (UK) where at least one twin from each pair underwent a hysterectomy (19). Snieder et 
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al. found the heritability of fibroids as an indication of hysterectomy to be 69% (19). In the 
second twin study, Luoto et al. (2000) examined heritability of fibroid number using a smaller 
sample size of 17 MZ and 16 DZ twin pairs from ages 40 and 47 from the Finnish Twin Cohort 
who underwent an ultrasound (20). Luoto et al. observed that the mean fibroid number was 1.7 
for fibroid cases and 1.1 for all women (including fibroid controls) and estimated the heritability 
of fibroid number to be 26% (20).  
 
 There has been one previous study estimating the heritability of fibroids using common 
genetic variants derived from GWAS data (43). The study by Ge et al. (2017) had a sample size 
of 57,151 women from the UK Biobank from ages 40 to 69 with a fibroid prevalence of 2.77% 
that was self-reported (43). Ge et al. estimated that fibroids are 8.71% heritable (43). In a study 
by Baird et al. (2003), the authors observed that 51% of premenopausal women without a 
previous fibroid diagnosis from the ages of 25 to 49 were diagnosed with a fibroid after having 
an ultrasound (2). Furthermore, Baird et al. found that the cumulative incidence of fibroids 
approached 70% for white women in the US (2). The large discrepancy between prevalence 
estimates between the two studies could signal potential misclassification for fibroid controls 
resulting in a lower heritability estimate in the Ge et al. study.  
 
 Somatic Mutations 
 
 Even though fibroids have an unknown etiology (40), there are numerous recurrent 
mutations that occur in fibroid tissue (11, 26, 44, 45). While up to 60% of fibroids are 
karyotypically normal (45), it is estimated that approximately 40-50% of fibroids have 
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cytogenetic abnormalities (11, 26, 44, 45), and these cytogenetic abnormalities are tumor-
specific and nonrandom (11). The most common chromosomal translocation includes t(12;14) 
(q14-q15; q23-24) being present in approximately 20% fibroid tumors with chromosomal 
rearrangements (44, 45). Other common chromosomal alterations include del(7)(q22q32) (17%) 
(11, 45) and 6p21 (11, 44-47) (~5%) (11). Less common chromosomal aberrations include 
chromosomes X, 1, 3, 5, 10, 12, and 13 (45). Fibroids that are karyotypically abnormal tend to be 
larger than karyotypically normal fibroids (44). 
 
 The break points within 12q15 from t(12;14) (q14-q15; q23-24) mostly occur upstream of 
gene promoter high mobility group AT-hook 2 (HMGA2), leading to increased HMGA2 
expression (44). The other rearrangement including 6p21 encompasses high mobility group AT-
hook 1 (HMGA1) (11, 45, 47). Interestingly, the high mobility group A (HMGA) subfamily 
moderates the activity of receptors for progesterone and estrogen (47). The genes HMGA1 and 
HMGA2 are aberrantly overexpressed in fibroid tissue likely resulting from their corresponding 
chromosomal rearrangements in either 12q15 or 6p21 (47). In contrast to HMGA1 expression, 
HMGA2 is not expressed in normal myometrium tissue (45). Likely related to HMGA1 
sometimes being expressed in normal myometrial tissue, HMGA1 expression has been found in 
fibroid tumors that are karyotypically normal (45). Cytogenic alterations involving HMGA1 and 
HMGA2 are associated with other benign mesenchymal tumors including endometrial polyps, 
pulmonary chondroid hamartomas, and lipomas (47). Expression of HMGA1 has also been 
associated with various carcinomas including mammary, prostate, and colorectal carcinomas 
(47). Fibroids with chromosomal rearrangements affecting HMGA2 are associated with increased 
fibroid size (44). 
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 In addition to chromosomal aberrations, there are recurrent mutations that occur in 
specific genes (44). The most commonly mutated gene in fibroids is mediator complex subunit 
12 (MED12) (44) in Xq13.1, which  is part of the Mediator complex that helps regulate gene 
expression levels (48). The mutation rate for MED12 is between 50-85% for all fibroids with the 
majority of mutations occurring in exons 1 or 2 (44, 49). It is thought that mutations in MED12 
might lead to fibroid formation (49). Interestingly, fibroids with MED12 mutations are associated 
with smaller fibroids (44).  
 
 Animal Models 
 
 There are animal models for uterine fibroids (14). A lesser used animal model includes 
the guinea pig (14). The prevalence of fibroids among aged guinea pigs is approximately 8%, but 
ovariectomy combined with estrogen supplementation can increase the frequency of fibroid 
development (14). The best-characterized animal model that is most similar to human fibroid 
development, however, is the Eker rat (14). The Eker rat is unique in that one copy of tuberous 
sclerosis complex 2 (Tsc2) gene is deactivated by a retroviral insertion and spontaneously forms 
fibroids at a frequency of approximately 65% (47). Loss of heterozygosity (LOH) of the Tsc2 
gene occurs at a frequency of ~50% in fibroid tissue, while loss of Tsc2 gene expression occurs 
for nearly all fibroids (47). Similarly to human fibroids and fibroid risk, Eker rat fibroid tumors 
are benign and have a hormonal component (47). The Eker rat fibroids do not form if an 
ovariectomy is performed by 4 months of age (47). Pregnancy is protective against Eker rat 
fibroid formation (47). In addition, the Eker rat hmga2 gene, which is the homolog to human 
HMGA2, is aberrantly expressed fibroid tissue (47). While human fibroid cell lines lose their 
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estrogen responsiveness causing it difficult to study hormone drug treatments in vitro, Eker rat 
cell lines maintain responsiveness to estrogen (47). This retention of sensitivity to hormones such 
as estrogen (47) makes the Eker rat a valuable animal model for research on fibroids. 
 
 Genome-wide Association Studies 
 
 There have been two prior GWAS on fibroid risk with the most significant index SNPs 
shown in Table 1.2 (50, 51). The first GWAS by Cha et al. (2011) found three loci, 10q24.33 
(rs7913069; odds ratio [OR] = 1.47; p = 8.65x10
-14
), 22q13.1 (rs12484776; OR = 1.23; p = 
2.79x10
-12
), and 11p15.5 (rs2280543; OR = 1.39; p = 3.82x10
-12
) associating with fibroid risk 
using women from the BioBank Japan Project (50). These genetic findings have been replicated 
(52). For example, Edwards et al. (2013) replicated associations in rs2280543 in blocked early in 
transport 1 homolog (BET1L) and in rs12484776 in trinucleotide repeat containing 6b (TNRC6B) 
in fibroid risk from a meta-analysis of candidate SNPs using two cohorts composed of women of 
European ancestry (52). These genetic findings have also been implicated with fibroid size. In an 
additional study, Edwards et al. (2013) found that the SNP, rs12484776, in 22q13.1 within the 
gene TNRC6B associated with increasing fibroid volume from a cohort of women of European 
ancestry from the Right from the Start cohort (53). In the second GWAS, Hellwege et al. (2017) 
performed meta-analyses from GWAS on fibroid risk using datasets of AA women from EHR 
populations. The authors observed a genome-wide significant association between rs739187 in 
cytohesin 4 (CYTH4) in 22q13.1 and fibroid risk (51). There have been no prior GWAS on 
fibroid characteristics such as fibroid size or number. 
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Table 1.1. Selected Fibroid Risk Factors for each exposure. 
Study Exposure N aOR (95% CI) 
Baird et al. (2003) (2) Race
a 
  
      White - 1.00 (referent) 
      Black - 2.7 (2.3, 3.2)
 
Velez Edwards et al. (2017) (18) Type 2 Diabetes
b 
2,353  
      No  1.00 (referent) 
      Yes  0.61 (0.47, 0.80) 
Study Exposure N* aRR (95% CI) 
Marshall et al. (1998) (35) Age at Menarche
c 
  
      ≤10 313 1.24 (1.08, 1.41) 
      11 584 1.11 (1.00, 1.23)
 
      12 930 1.00 (referent) 
      13 748 0.91 (0.82, 1.00)
 
      14-15 367 0.87 (0.77, 0.98)
 
      ≥16 64 0.68 (0.53, 0.88) 
 Parity Status
c 
  
      Nulliparous 949 1.00 (referent) 
      Parous 2,026 0.67 (0.61, 0.74) 
Marshall et a. (1988) (38) BMI
d 
  
      <20.0 309 0.90 (0.79, 1.03) 
      20.0-21.9 655 1.00 (referent) 
      22.0-23.9 584 1.08 (0.97, 1.21) 
      24.0-25.9 458 1.16 (1.03, 1.31) 
      26.0-27.9 262 1.21 (1.05, 1.40) 
      28.0-29.9 209 1.36 (1.16, 1.59) 
      ≥30.0 481 1.23 (1.09, 1.39) 
Study Exposure N Matched Relative Risk 
Ross et al. (1986) (37) BMI   
      <19 59 1.00 
      19-20.9 241 1.85 
      21-22.9 347 2.17 
      23-24.9 242 2.51 
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      25-26.9 88 2.88 
      ≥27 93 2.47 
 Parity   
      0 89 1.00 
      1 143 0.87 
      2 515 0.47 
      3 225 0.43 
      4 67 0.39 
      5 31 0.24 
Study Exposure N Rate/1000 women years 
Ross et al. (1986) (37) Age   
      25-29 7 0.31 
      30-34 48 0.96 
      35-39 169 2.67 
      40-44 201 4.63 
      45-49 103 6.20 
      ≥50 10 4.24 
N-number; BP-base pairs; OR-odds ratio; CI-confidence interval; aOR-adjusted odds ratio; RR-relative risk; aRR-adjusted relative risk; BMI-body mass index. 
a
 Model adjusted for BMI and parity. 
b
 Model adjusted for age, BMI, and race. 
c
 Model adjusted for age, race, marital status, age at menarche, age at first birth, years since last birth, age at first oral contraceptive use, and history of infertility. 
d
 Model adjusted for age, race, marital status, age at menarche, body mass index, age at first birth, years since last birth, age at first oral contraceptive use, and 
history of infertility. 
*Number of cases only. 
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Table 1.2. Index SNPs from GWAS of Fibroid Risk. 
Study Chr Region BP  SNP A2/A1 OR (95% CI) P-value 
Cha et al. (2011) (50) 10q24.33 105,715,399 rs7913069 A/G 1.47 (1.23, 1.75) 8.65x10
−14
 
 22q13.1 40,652,873 rs12484776 G/A 1.23 (1.11, 1.37) 2.79x10
−12
 
 11p15.5 203,788 rs2280543 G/A 1.39 (1.17, 1.64) 3.82x10
−12
 
Hellwege et al. (2017) (51) 22q13.1 37,728,254 rs739187 T/C 1.23 (1.16, 1.30) 7.83x10
−09
 
 3p26.1 5,348,595 rs55768811 A/T 0.76 (0.66, 0.87) 2.62x10
−07
 
 8q21.11 75,119,342 rs6472827 T/C 0.76 (0.65, 0.86) 3.89x10
−07
 
 8p23.2 4,441,780 rs11987640 C/G 0.81 (0.73, 0.89) 4.85x10
−07
 
Chr-chromosome; BP-base pairs; SNP-single nucleotide polymorphism; A2-effect allele; A1-reference allele; OR-odds ratio; CI-confidence interval. BP 
positions are based on the reference genome build GRCh37.p13. 
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CHAPTER 2  
 
EVALUATING RISK FACTORS FOR DIFFERENCES IN FIBROID SIZE AND NUMBER 
USING A LARGE ELECTRONIC HEALTH RECORD POPULATION 
 
INTRODUCTION 
 As noted in Chapter 1, fibroids are a heterogeneous disease with many health 
implications. Some women develop a single, small fibroid while others develop large and/or 
multiple fibroids. Multiple fibroids have been found to be associated with preterm birth and 
cesarean delivery, while large fibroids have been found to be associated with preterm premature 
rupture of membranes (30).  
 Increasing BMI (kg/m
2
) (10), nulliparity (15, 16), and black race (11-14) have been 
previously associated with fibroid risk. Additionally, type 2 diabetes has been shown to be 
protective for fibroids (17, 18). Although there are well documented studies examining fibroid 
risk factors (10-15), there is limited understanding of factors associated with fibroid size and 
number. One potential reason for the lack of studies on fibroid characteristics is because fibroid 
size and number can only be assessed by imaging or surgical procedures (such as ultrasounds or 
hysterectomies).  
 Few studies examine the risk factors for fibroid characteristics. In one study by Velez 
Edwards et al., the authors associated decreasing age at menarche with increasing fibroid number 
and size using the Right From the Start (2001-2010) cohort which had performed ultrasounds on 
5,023 women (540 cases) (9). In a cross-sectional study by Baird et al., the authors included 988 
women (630 cases) who had ultrasounds from the National Institute of Environmental Health 
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Sciences Uterine Fibroid Study and found that decreased levels of insulin-like growth factor-I 
was associated with having a small (<2 cm) and medium (≥2 to <4 cm) sized fibroid in white 
women and decreasing insulin levels was associated with having a large fibroid (≥4 cm), 
especially in black women (42). In another cross-sectional study by Moorman et al., the authors 
examined differences in fibroid characteristics and their risk factors between black and white 
women (N=360) undergoing hysterectomy from the Prospective Research on Ovarian Function 
study where all fibroid characteristic information was abstracted from pathology and operative 
notes (39). The authors found that black women on average had larger and more numerous 
fibroids than white women (39). The authors also found that nulligravid black and white women 
were more likely to have larger fibroids and only nulligravid white women were more likely to 
have multiple fibroids than women with one or more pregnancies (39). 
 Physical and clinical patterns of a woman may put her at risk of developing fibroids with 
specific characteristics, such as single versus multiple fibroids or a small versus large fibroid. 
Knowing which of these physical and clinical features are most associated with fibroid 
characteristics might allow for potential targeted fibroid treatments. Our objective was to identify 
physical and clinical features associated with fibroid size or number. We examined the 
association of fibroid characteristics (fibroid volume, largest fibroid dimension, and fibroid 
number) with candidate risk factors using a clinical cohort of 2,302 women identified from 
EHRs.  
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MATERIAL AND METHODS 
Study Population 
The Synthetic Derivative 
 We conducted our analyses using subjects from the Synthetic Derivative, a clinical 
dataset at VUMC (22) that consists of de-identified demographic and clinical information from 
patient EHRs.  
 We used a previously validated phenotyping algorithm with a positive predictive value of 
96% to identify fibroid cases (21). The algorithm included only black and white women who 
were 18 years or older, had at least one International Classification of Diseases, 9
th
 Revision 
(ICD-9) or current procedure terminology (CPT) codes for pelvic imaging, and at least one ICD-
9 or CPT code indicating a fibroid diagnosis. Fibroid status for 2,302 cases was manually 
validated by examining image or surgical reports from patient EHRs. We manually extracted 
dimensions for each reported fibroid, number of fibroids, and relevant demographic information 
from pelvic imaging reports including ultrasound, magnetic resonance imaging, and computed 
tomography (CT) scans or surgical reports from myomectomies and hysterectomies. Precedence 
for recording patient information was given to the first image report mentioning fibroids. If a 
patient’s EHR lacked an image report citing fibroids, we entered patient data from the first 
surgical report describing their fibroids.  
 Abstracted fibroid characteristics included fibroid number (single vs. multiple), volume 
of largest fibroid (centimeter cubed [cm
3
]), and largest dimension (cm) of all reported fibroids. 
The following formula for volume of an ellipsoid was used to calculate fibroid volume: (Length 
x Width x Height x 0.523). The largest fibroid dimension and volume measurements were log10 
transformed to accommodate the assumption of normally distributed residuals for linear 
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regression. For individuals with only two recorded dimensions of their largest fibroid (35.6% of 
cases), we imputed the last measurement by averaging the initial two to calculate fibroid volume, 
assuming the first two measurements were predictive of the missing third measurements. For 
individuals with data for number of fibroids, some EHRs (18.6%) noted the presence of many 
fibroids but gave no specific number. Because of this limitation, we coded fibroid number as one 
versus multiple fibroids.  
 Abstracted fibroid risk factors included age at diagnosis, BMI (continuous), self-reported 
or clinically identified race, type 2 diabetes status, and number of living children. We used 
previously published programming algorithms to abstract type 2 diabetes from EHRs (54). 
Number of living children was chosen as a proxy for parity. This study has been evaluated and 
approved by the Vanderbilt University Medical Center Institutional Review Board. 
Statistical Analyses 
 We performed univariate and multivariate regression analyses on the outcomes volume of 
largest fibroid, largest dimension of all fibroids, or number of fibroids (single vs. multiple). 
Exposures included age at diagnosis, BMI, self- or third-party-identified race, type 2 diabetes 
status, and number of living children (a proxy for parity) as covariates. All multivariate 
regression analyses included age, BMI, and race as covariates. Age and BMI were not normally 
distributed and had nonlinear effect sizes; therefore analyses were performed grouping age into 
quintiles and BMI into World Health Organization (WHO) categories (55). There were too few 
underweight individuals to be included in statistical analyses (underweight N=27), so we 
combined individuals from the underweight and normal weight categories. We assessed potential 
effect measure modification by race on age quintiles and BMI categories using a likelihood ratio 
test comparing the full model with interaction term to the same model lacking the interaction 
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term, and a likelihood ratio test p-value of 0.10 or less was considered significant. Because we 
did not observe effect measure modification within our dataset, we did not stratify the analyses 
by race. 
 In secondary analyses multiple imputation (MI) was performed for missing data (number 
of living children) for each outcome to determine if missingness in this exposure significantly 
affected our analyses. All exposures in the multivariate regression model and the outcome were 
included in each MI data model. Each dataset was imputed ten times. To ensure consistency in 
MI analyses, the random-number generation functions were seeded with the number 12,345. MI 
analyses were largely consistent with effect sizes estimated from non-imputed data; therefore, we 
present and discuss results using non-imputed missing data.  
We used Stata/SE 13 (College Station, Texas) for all statistical analyses. 
 
RESULTS 
Demographic Data 
 There were 2,302 individuals with fibroids within our study population (Table 2.1). The 
mean age was 45.5 years ± 12, and the majority of women were either overweight (29%) or 
obese (44%) with a mean BMI of all women being 30.4 kg/m
2
. The median volume of largest 
fibroid and largest fibroid dimension were 12.6 cm
3
 and 2.9 cm, respectively. Additionally, about 
half of the women had multiple fibroids (52%). 
Fibroid Number 
Increasing age when compared to the referent groups (first quintile) was significantly 
associated with multiple fibroids (Table 2.2). The strongest association was observed when 
comparing ages 43 to 47 to the referent group (ages 18 to 36) (adjusted odds ratio [aOR]: 3.37; 
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95% confidence interval [CI]: 2.55, 4.46). Additionally, black race was significantly associated 
with having multiple fibroids (aOR: 1.83; 95% CI: 1.49, 2.24). BMI and type 2 diabetes were not 
associated with fibroid number. Finally, increasing number of living children was associated 
with having multiple fibroids (aOR: 0.88; 95% CI: 0.78, 0.99). 
Fibroid Size (Volume and Largest Dimension) 
  Increasing age significantly was associated with larger fibroid volume when comparing 
age groups 43 to 47 (adjusted beta: 1.47; 95% CI: 1.05, 2.07) and 48 to 54 (adjusted beta: 1.57; 
95% CI: 1.12, 2.22) to the referent group (ages 18 to 36) (Table 2.3). Increasing age was also 
significantly associated with larger fibroid dimensions when comparing age groups 43 to 47 
(adjusted beta: 1.16; 95% CI: 1.04, 1.30) and 48 to 54 (adjusted beta: 1.19; 95% CI: 1.07, 1.32) 
to the referent group (ages 18 to 36) (Table 2.4). Black race was significantly associated with 
increasing fibroid volume (adjusted beta: 1.77; 95% CI: 1.38, 2.27) and largest dimension 
(adjusted beta: 1.28; 95% CI: 1.18, 1.38). BMI and type 2 diabetes were not associated with 
fibroid size. Number of living children was not associated with fibroid volume or largest 
dimension. 
 
DISCUSSION 
 To our knowledge we conducted the largest study evaluating the relationship between 
fibroid characteristics and clinical and physical features. In this study, we observed no effect 
modification by race in analyses of age or BMI and fibroid characteristics. We observed the 
strongest associations between age and multiple fibroids when comparing ages 43 to 47 to the 
referent group, and the strongest associations between age and increasing fibroid volume and 
largest fibroid dimension was later between ages 48 to 54. We observed that black race is 
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strongly associated with larger fibroid sizes and increasing number of fibroids. We observed no 
associations between fibroid characteristics and BMI or type 2 diabetes. Finally, we observed 
that having more children was associated with single fibroids. These results are consistent with 
phenotypic heterogeneity in the fibroid phenotype; in that not all women have fibroids because 
of the same set of risk factors. For example, there are different risk factors for a woman getting a 
single fibroid than there are for developing multiple large fibroids.  
Risk for having multiple fibroids peaked between ages 43 and 47, while risk having for 
larger fibroids peaked later between ages 48 to 54. This is overall consistent with fibroid risk that 
also increases until menopause (2). In a study by Baird et al. (2003), increasing clinically 
relevant fibroid prevalence for both white and black women was associated with increasing age 
between 35 and 49 (2). We observed that risk for having multiple fibroids increased and peaked 
when women reached premenopause/early menopause age and then that risk declined for 
subsequent age groups, across all age analyses (fibroid number, volume, and largest dimension). 
Interestingly, Cramer and Patel (1990) estimated the prevalence estimate of fibroids by 
performing serial sectioning of uterine tissue from 100 consecutive hysterectomies (28). The 
authors found that while there was little difference in fibroid risk with regards to menopausal 
status (28). The authors also found that postmenopausal women were found to have smaller and 
fewer fibroids compared to premenopausal women. These observations support a hormonal 
influence on having larger and more numerous fibroids. In addition, fibroids have not been 
documented in prepubescent girls (25), since fibroids have a hormonal component. It could be 
possible that fibroids form and progress only after many years of exposure to hormones 
including estrogen and progesterone. After events like menopause where estrogen and 
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progesterone levels are reduced, fibroids progression/development is stunted. This information is 
supported by postmenopausal women having less surgery for fibroid-related reasons (34).  
Increasing BMI was not associated with either fibroid number or size. In a previous 
study, Dandolu et al. (2010) found that increasing BMI was associated with fibroid risk but not 
with fibroid largest dimension (10). The authors dichotomized fibroid size as greater than or less 
than two centimeters and included 533 women (10). The lack of an association between BMI and 
fibroid characteristics could mean that BMI influences fibroid risk only and not progression. 
 Type 2 diabetes was not significantly associated with fibroid number or size in our study. 
It should be noted, however, that type 2 diabetes tended to be associated with single and smaller 
fibroid volume. Diabetes has been inversely associated with fibroid risk. In 2017, Velez Edwards 
et al. observed a protective effect of diabetes on fibroid risk (aOR: 0.61; 95% CI: 0.47, 0.80) 
(18). Studies between diabetes and fibroid characteristics are limited. In the Baird et al. study 
(2009), the authors performed association analyses between diabetes metabolites and fibroid size 
in white and black women. The authors observed an inverse association between insulin-like 
growth factor-I and fibroid size in both white and black women (42). The authors only had 
approximately 92 individuals with diabetes (including gestational diabetes) and could not 
perform association analyses between diabetes and fibroid size (42). There were only 317 
women that were diabetic in our dataset. The lack of an association between type 2 diabetes and 
fibroid number and size could mean that our sample size was too small. Future studies with a 
larger diabetic population should examine the association between type 2 diabetes and fibroid 
characteristics. 
 We found that having more children was associated with having fewer fibroids 
suggesting that pregnancy may reduce the number of fibroids present. We also observed 
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nonsignificant trends between increasing number of living children and smaller fibroid sizes. 
This is consistent with literature showing that women with a higher parity are at a reduced risk 
for fibroids (relative risk: 0.5; 95% CI: 0.4-0.6) (16). The protective effects of carrying a child to 
term could not only decrease the risk of having fibroids but also the number of fibroids only (not 
fibroid size). More studies are needed to assess the association between number of living 
children/parity and fibroid characteristics.  
 Parity was not consistently documented in the EHRs, and we used number of living 
children as a proxy. Additionally, prior studies examining the relationship between fibroid 
characteristics and fibroid risk factors compared each characteristic to controls. With that 
approach it is difficult to determine if the observed effect is due to a woman having a fibroid or 
to having specific fibroid characteristics.   
 Using a dataset of EHRs consisting of women with image- or surgery-confirmed fibroids, 
we found that black race was associated with multiple and larger fibroids. We also observed that 
increasing age was nonlinearly associated with multiple and larger fibroids with risk for multiple 
and larger fibroids being different, respectively, for different age groups. Lastly, we observed 
that multiple fibroids and not size were associated with increasing number of living children. Our 
findings are consistent with the phenotypic heterogeneity of fibroids and suggest that there may 
be different underlying etiology involved with women developing single versus multiple fibroids 
and small versus large fibroids. Additionally, these findings suggest that physical and clinical 
features of a woman may help to determine if and when she is at risk of developing fibroids with 
specific characteristics. These results can potentially guide a physician towards the best route of 
fibroid treatment.   
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Table 2.1. Demographic characteristics of study population. 
Characteristics N 
Synthetic Derivative 
Cohort 
Age (mean±SD) 2,302 45.5±12 
     18 to 36 (%) 510 22 
     37 to 42 (%) 438 19 
     43 to 47 (%) 442 19 
     48 to 54 (%) 493 21 
     55 to 87 (%) 419 18 
BMI (kg/m
2
) (mean±SD) 2,302 30.4±8 
     Underweight (<18.5) (%) 27   1 
     Normal Weight (18.5-24.9) (%) 606 26 
     Overweight (25-29.9) (%) 663 29 
     Obese (≥30) (%) 1,006 44 
Race (%) 2,302  
     White 1,616 70 
     Black 686 30 
Fibroid Volume (cm
3
) median (IQR) 1,307 12.6 (2.7, 47.6) 
Largest Fibroid Dimension (cm) median (IQR) 1,777 2.9 (1.7, 4.8) 
Fibroid Number (%) 2,149  
     1  1,042 48 
     >1  1,107 52 
Type 2 Diabetes Status (%) 2,302  
     No 1,985 86 
     Yes 317 14 
Number of Children (%) 692  
     0 160 23 
     1 107 15 
     2 242 35 
     3 113 16 
     4 39   6 
     5 20   3 
     >6 11   2 
BMI-body mass index; cm
3
-cubic centimeters; SD-standard deviation; IQR-interquartile range. 
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Table 2.2. Association between fibroid number and exposures. 
Exposures N Crude OR [95% CI] Crude P-value Adjusted 
a
 OR [95% CI] Adjusted 
a
 P-Value 
Age
 
2,149     
     18 to 36 474 1.00 (referent) - 1.00 (referent) - 
     37 to 42 405 1.79 [1.36, 2.34] <0.001 1.85 [1.41, 2.44] <0.001 
     43 to 47 417 3.07 [2.34, 4.04] <0.001 3.37 [2.55, 4.46] <0.001 
     48 to 54 465 2.09 [1.61, 2.72] <0.001 2.48 [1.89, 3.25] <0.001 
     55 to 87 388 1.84 [1.40, 2.41] <0.001 2.17 [1.64, 2.89] <0.001 
BMI (kg/m
2
)
 
2,149     
     Normal Weight* 595 1.00 (referent) - 1.00 (referent) - 
     Overweight 623 1.21 [0.96, 1.51] 0.102 1.08 [0.85, 1.36] 0.527 
     Obese 931 1.07 [0.87, 1.32] 0.513 0.93 [0.75, 1.16] 0.530 
Race 2,149     
     White 1,503 1.00 (referent) - 1.00 (referent) - 
     Black 646 1.52 [1.27, 1.84] <0.001 1.83 [1.49, 2.24] <0.001 
Type 2 Diabetes Status 2,149     
     No 1,858 1.00 (referent) - 1.00 (referent) - 
     Yes 291 0.94 [0.73, 1.20] 0.623 0.77 [0.59, 1.01] 0.055 
Number of Living Children 631 0.93 [0.83, 1.04] 0.213 0.88 [0.78, 0.99] 0.036 
CI-confidence interval; BMI-body mass index; kg/m
2
-kilogram per meter squared. 
a 
Adjusted for age quintiles, WHO BMI categories, and race, respectively. 
*Due to the limited number of underweight subjects (N=27) normal weight includes underweight individuals. 
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Table 2.3. Association between fibroid volume and exposures. 
Exposures N Crude Beta** [95% CI] Crude P-value Adjusted 
a
 Beta** [95% CI] Adjusted 
a
 P-Value 
Age
 
1,307     
     18 to 36 313 1.00 (referent) - 1.00 (referent) - 
     37 to 42 258 1.19 [0.85, 1.68] 0.311 1.22 [0.86, 1.71] 0.262 
     43 to 47 261 1.40 [0.99, 1.97] 0.054 1.47 [1.05, 2.07] 0.027 
     48 to 54 276 1.33 [0.95, 1.86] 0.102 1.57 [1.12, 2.22] 0.010 
     55 to 87 199 0.70 [0.48, 1.01] 0.055 0.81 [0.56, 1.18] 0.281 
BMI (kg/m
2
)
 
1,307     
     Normal Weight* 344 1.00 (referent) - 1.00 (referent) - 
     Overweight 377 1.42 [1.05, 1.93] 0.025 1.31 [0.97, 1.78] 0.083 
     Obese 586 1.32 [1.00, 1.75] 0.049 1.13 [0.85, 1.50] 0.408 
Race 1,307     
     White 844 1.00 (referent) - 1.00 (referent) - 
     Black 463 1.75 [1.38, 2.21] <0.001 1.77 [1.38, 2.27] <0.001 
Type 2 Diabetes Status 1,307     
     No 1,141 1.00 (referent) - 1.00 (referent) - 
     Yes 166 0.78 [0.55, 1.09] 0.149 0.72 [0.51, 1.02] 0.062 
Number of Living Children 345 0.97 [0.82, 1.14] 0.696 0.93 [0.79, 1.11] 0.422 
CI-confidence interval; BMI-body mass index; kg/m
2
-kilogram per meter squared. 
a 
Adjusted for age quintiles, WHO BMI categories, and race, respectively. 
*Due to the limited number of underweight subjects (N=27) normal weight includes underweight individuals.  
**Betas are back-transformed to cm
3
. 
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Table 2.4. Association between largest fibroid dimension and exposures. 
Exposures N Crude Beta** [95% CI] Crude P-value Adjusted 
a
 Beta** [95% CI] Adjusted 
a
 P-Value 
Age
 
1,777     
     18 to 36 408 1.00 (referent) - 1.00 (referent) - 
     37 to 42 345 1.05 [0.94, 1.18] 0.347 1.06 [0.95, 1.19] 0.264 
     43 to 47 345 1.13 [1.02, 1.27] 0.026 1.16 [1.04, 1.30] 0.007 
     48 to 54 381 1.11 [1.00, 1.24] 0.051 1.19 [1.07, 1.32] 0.002 
     55 to 87 298 0.88 [0.78, 0.98] 0.024 0.94 [0.84, 1.05] 0.284 
BMI (kg/m
2
)
 
1,777     
     Normal Weight* 491 1.00 (referent) - 1.00 (referent) - 
     Overweight 510 1.10 [1.00, 1.21] 0.043 1.06 [0.97, 1.17] 0.200 
     Obese 776 1.11 [1.02, 1.22] 0.015 1.05 [0.96, 1.14] 0.319 
Race 1,777     
     White 1,209 1.00 (referent) - 1.00 (referent) - 
     Black 568 1.28 [1.18, 1.38] <0.001 1.28 [1.18, 1.38] <0.001 
Type 2 Diabetes Status 1,777     
     No 1,545 1.00 (referent) - 1.00 (referent) - 
     Yes 232 0.98 [0.88, 1.08] 0.644 0.94 [0.84, 1.05] 0.278 
Number of Living Children 491 0.98 [0.94, 1.03] 0.517 0.96 [0.92, 1.01] 0.155 
CI-confidence interval; BMI-body mass index; kg/m
2
-kilogram per meter squared. 
a 
Adjusted for age quintiles, WHO BMI categories, and race, respectively. 
*Due to the limited number of underweight subjects (N=27) normal weight includes underweight individuals.  
**Betas are back-transformed to cm. 
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CHAPTER 3  
 
ESTIMATING MISSING HERITABILITY OF UTERINE FIBROIDS USING COMMON 
SNPS FROM A CLINICAL COHORT COMPOSED OF EUROPEAN AMERICAN WOMEN 
 
INTRODUCTION 
 As described in Chapter 1, fibroids are heritable with twin studies estimating fibroid 
heritability to be between 26 to 69% among EA women (19, 20). One study previously estimated 
the heritability of fibroids using common genetic variants derived from genome-wide SNP data 
(43). The study by Ge et al. (2017) had a sample size of 57,151 UK women with a fibroid 
prevalence of 2.77% that was self-reported (43). Ge et al. estimated that fibroids are 8.71% 
heritable (43). 
 Two prior GWAS have been performed on fibroids (50, 56) in order to discover the 
genetic variants associated with fibroids. The first GWAS by Cha et al. (2011) found three loci, 
10q24.33 (rs7913069; OR = 1.47; p = 8.65x10
-14
), 22q13.1 (rs12484776; OR = 1.23; p = 
2.79x10
-12
), and 11p15.5 (rs2280543; OR = 1.39; p = 3.82x10
-12
) associated with fibroid risk in a 
Japanese cohort (50). These genetic findings have been replicated (52). For example, Edwards et 
al. (2013a) associated rs2280543 in BET1L and rs12484776 in TNRC6B with fibroid risk using 
two cohorts of EA women (52). In an additional study, Edwards et al. (2013b) found that the 
SNP, rs12484776, in 22q13.1 within the gene TNRC6B associated with increasing fibroid 
volume from a cohort of women of European ancestry from the Right from the Start cohort (53). 
In another GWAS, Hellwege et al. (2017) performed meta-analyses from GWAS on fibroid risk 
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using datasets of AA women from an EHR population. The authors observed a genome-wide 
significant association between rs739187 in CYTH4 in 22q13.1 and fibroid risk (51). 
 GWAS are a powerful tool to find common genetic variants that associate with disease. 
As expected based on the available sample sizes, current GWAS of fibroids have identified only 
a few variants that explain a small proportion of fibroid risk. Better characterization of fibroid 
heritability is needed to understand the genetic architecture influencing risk for fibroids. 
Additionally, imaging is critical in genetic studies on fibroids because as much as 51% of women 
whose status is not image-confirmed and who may be asymptomatic can be misclassified as 
controls (2). In this study, we propose estimating and characterizing the heritability of image-
confirmed fibroids in EA women using GWAS data. 
 
MATERIALS AND METHODS 
Study Population 
BioVU 
The BioVU DNA Repository (2007-present) is a de-identified database of EHRs that is 
linked to DNA. BioVU consists of stored de-identified demographic and clinical information for 
each patient who visits the VUMC and chooses to participate (22). A detailed description of 
BioVU has been previously described (22, 57). The Office of Human Research Protections and 
the Institutional Review Boards deemed the BioVU DNA repository as non-human subjects 
research (57).  
 Fibroid cases and controls were identified using a validated phenotyping algorithm with a 
positive predictive value of 96% and a negative predictive value of 98% (21). The same fibroid 
case phenotyping algorithm that was used in Chapter 2 on the Synthetic Derivative was applied 
in this study on EA women. Controls were at least 18 years old, had at least two ICD-9 or CPT 
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codes for pelvic imaging, and had no history of myomectomy, hysterectomy, or UAE (21) and 
were group matched by ancestry to cases. We also conducted a case-only analysis to evaluate the 
heritability of fibroid size. In order to determine fibroid size, we manually abstracted fibroid 
measurements from imaging and surgical reports. Patient demographic information was recorded 
at the time of diagnosis.  
 Outcome measurements include fibroid presence (case vs control), largest fibroid 
dimension of all measurements, and largest fibroid volume. Fibroid volume was calculated using 
the equation of an ellipsoid: (Length x Width x Height x 0.523). In order for the outcome to have 
a normal distribution, fibroid largest dimension and volume were log10 transformed. 
Approximately a third of individuals with volume measurements had their third dimension 
measurement imputed by taking the mean of the first two measurements. 
Genotyping 
 Genotyping of BioVU EA individuals was performed on the Affymetrix Axiom Biobank 
array (Affymetrix, Inc., Santa Clara, CA) using PicoGreen (Invitrogen, Inc., Grand Island, NY) 
to purify and to quantify the DNA. 
GWAS Quality Control (QC) 
 Genetic data had standard QC prior to imputation using PLINK 1.07 software (58). Pre-
imputed QC included: removing subjects with low genotyping efficiency (<95%), removing 
related individuals (both individuals from a pair with a probability of identity by descent [IBD] > 
0.95 and one from a pair with a probability of IBD from 0.2-0.95), removing individuals with 
inconsistency between genetic and reported sex. Additionally, we removed SNPs out of HWE 
(p≤10-6), SNPs with a low genotyping efficiency (<95%), SNPs with a minor allele frequency 
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(MAF) < 0.01, and SNPs without a chromosome location. Finally, SNPs were aligned to the + 
strand of the 1000 Genomes (build 37, 2013). 
 We imputed non-genotyped SNPs using IMPUTE2.3.0 software (59) and subsequently 
converted the imputed genetics to PLINK 1.07 format (58) after filtering SNPs with an info score 
≤0.95 and removing insertion/deletion polymorphisms. We then applied GCTA-specific QC that 
was performed by Hong Lee et al. (2011) (60) which included: removing SNPs with a MAF < 
0.05, removing related individuals (one from a pair with a probability of IBD >0.05, and 
removing SNPs out of HWE (≥0.05). Post-QC SNP numbers included 4,500,362 for fibroid risk, 
4,522,829 for fibroid volume, and 4,518,340 for largest fibroid dimension (Appendix A).  
Statistical Analyses 
 Covariate and demographic data were summarized by Stata/SE (College Station, Texas). 
Principal components (PCs) were created using EIGENSTRAT4.2 software (61). To reduce 
admixture within BioVU, we removed all samples whose first PC (PC1) and second PC (PC2) 
were more than four standard deviations from the mean of PC1 and PC2 of the European (EUR) 
individuals (Appendix B, Appendix C). 
We estimated the genetic variance explained by all SNPs using GCTA software (23). 
GCTA creates a genetic relationship matrix (GRM) between pairs of individuals within a cohort 
using all SNPs. GCTA uses a mixed linear model (MLM) that estimates the genetic variance 
explained by all SNPs for a trait using the restricted maximum likelihood approach (REML) 
(23). The final model for fibroid risk included the GRM which was modeled as a random effects 
term and the fixed effects terms age, BMI, and top five PCs. We transformed the observed 
estimate of heritability to the liability scale using a fibroids prevalence estimate of 70%. A 
prevalence estimate of 70% was used in models on fibroid risk because the mean age of our 
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cohort was 50.8 and previous cumulative incidence estimates were ~70% for women near 51 
years of age (2). Heritability estimates for a range of prevalence estimates are shown in 
Appendix D. Secondary analyses included estimating heritability of fibroid size, namely volume 
and largest dimension. Final models for fibroid volume and max dimension adjusted for age, 
BMI, and five PCs without a prevalence estimate. Additional heritability estimates were 
calculated adjusting for age, BMI, and varying numbers of PCs to show that potential residual 
population stratification did not lead to spurious heritability estimates. 
To characterize the genetic architecture of fibroids, we partitioned the genetic variance 
into separate GRMs by chromosomes, by genic and intergenic regions. We annotated SNP 
location into genic/intergenic regions using ANNOVAR software (62). We used a distance of 
one kilobase (kb) from a transcript as the boundary threshold for genic and intergenic SNPs. For 
the analysis partitioned by functional category (intergenic vs. genic), we used a two-tailed 
binomial test to assess the difference in the proportion of heritability explained by each partition, 
given the number of SNPs. Additional subanalyses involved excluding genomic regions 
previously implicated in fibroid risk based on GWAS. Exclusion criteria included selecting SNPs 
from final meta-analyses of GWAS (50, 51) with a p-value ≤ 1.00x10-6 and subsequently 
removing all loci ± 0.5 mega bases (Mb) of these selected SNPs. Lastly, there is a common 
inversion that spans approximately 12 centimorgan (cM) on chromosome 8 encompassing 
8p23.1-8p22 with a frequency of approximately 21% in European populations (63). We 
determined the effect that this inversion has on fibroid risk by removing it from chromosome-
specific heritability estimates and comparing the difference in point estimates.  
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RESULTS 
Demographic Data 
 There were 2,109 EA women (1,067 cases and 1,042 controls) with image-confirmed 
fibroid status within BioVU (Table 3.1). The mean age was 50.8±16 years, and the majority of 
women were overweight or obese (mean BMI: 28.6±7 km/m
2
). There were 373 cases with 
fibroid volume measurements (median of largest volume: 9.6 cm
3
) and 551 cases with fibroid 
dimension measurements (median of largest dimension: 2.6 cm).  
Heritability Estimates 
 The heritability estimate for fibroid risk, or the proportion of phenotypic variance that 
was explained by genetic variance, was h
2
 = 0.33±0.18, p-value 0.040 (Table 3.2), and this 
estimate was consistent after decreasing our MAF threshold to 1%. The heritability estimates for 
fibroid largest dimension was h
2
 = 0.35±0.47, p-value 0.238, and for volume was h
2
 = 0.14±0.66, 
p-value 0.417. These heritability estimates for each outcome were similar after adjusting for a 
range of PCs (risk h
2
: 0.29-0.38; largest dimension h
2
: 0.34-0.44; volume h
2
: 0.12-0.35) 
(Appendix E, Appendix F, Appendix G).  
Partitioning the genome into chromosomes and  into genic and intergenic regions 
 The correlation (r
2
) between chromosome length in base pairs and heritability per 
chromosome was 0.89% (p = 0.669) (Figure 3.1). Chromosome 8 explained the greatest 
proportion of variance for fibroid risk (8.76%), followed by chromosome 10 (5.57%), 11 
(5.11%), and 7 (2.65%). The summation of the heritability estimate of each chromosome was 
34%, which is not significantly different from the univariate estimate suggesting that residual 
population stratification and cryptic relatedness are well controlled (64). In addition, there is an 
approximately 12 cM common inversion present at a frequency of 21% in EA populations on 
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chromosome 8 spanning 8p23.1-8p22 (63). It is possible that this inversion could affect the 
disproportionate contribution of heritability for chromosome 8. Because of this, we estimated 
fibroid heritability on chromosome 8 excluding 8p23.1-8p22, 8p, and 8q, respectively (Figure 
3.2). We found that excluding 8p23.1-8p22 did not change the contribution of heritability from 
chromosome 8. We also found that most of the heritability from chromosome 8 was located in 
8q. Even though fibroids are a sex-linked disease and have a hormonal component especially 
with estrogen (14), we only observed slight heritability from chromosome X of about 1%.  
 We also partitioned the genetic data into genic and intergenic regions resulting in 
2,801,797 intergenic SNPs (62.3%) and 1,694,891 genic SNPs (37.7%) (Table 3.3). There was 
no enrichment for intergenic or genic SNPs for the heritability of fibroid risk (binomial test p-
value = 0.491) (Figure 3.3).  
Heritability explained by previous GWAS on fibroid risk 
 The genomic regions that met the exclusion criteria were 10q24.33-10q25.1, 11p15.5, 
and 22q13.1-22q13.2 from the Cha et al. (2011) GWAS (50) and 3p26.1, 8p23.2, 8q21.11, and 
22q12.3-22q13.1 from the Hellwege et al. (2017) GWAS (51). Excluding genetic loci previously 
associated with fibroid risk from all previous GWAS (50, 51) did not attenuate the estimated 
heritability of fibroid risk (h
2
 from all studies = 0.34) (Table 3.4).  
 
DISCUSSION 
 This was the first study to estimate and characterize the heritability of fibroids using a 
dataset of EA women with image-confirmed fibroid status. Estimated heritability of fibroid risk 
was 0.33±0.18. Chromosome 8 contributed the greatest proportion of heritability and we 
observed little correlation between chromosome length and chromosomal heritability, suggesting 
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that fibroid heritability is not evenly distributed throughout the genome. There was no 
enrichment of fibroid heritability for intergenic or genic regions. Finally, censoring genetic loci 
previously implicated with fibroid risk did little to attenuate the estimated heritability.  
 The heritability estimate of 33% for fibroid risk from our study is within the range of 
estimates from these twin studies (26-69%) (19, 20). In the first twin study, Snieder et al. (1998) 
found the heritability of fibroids to be 69% in a population of women who had hysterectomies 
(19). The authors had data on 98 MZ and 125 DZ twin pairs from the United Kingdom where at 
least one twin from each pair underwent a hysterectomy (19). The higher heritability from this 
study could be because Snieder et al. examined fibroid heritability as an indication for a 
hysterectomy selecting for patients who may have more severe fibroids. This higher heritability 
estimate could be for fibroids that cause symptoms leading to a hysterectomy. In the second twin 
study, Luoto et al. (2000) estimated the heritability of fibroid number to be 26% (20). This 
study’s heritability estimates while having a much smaller sample size of 17 MZ and 16 DZ twin 
pairs from the Finnish Twin Cohort (20) was closer to our fibroid risk heritability estimate.  
 Our heritability estimate (33%) was much higher than previous heritability estimates 
from genome-wide SNP data by Ge et al. (2017) (43). While Ge et al. had a much larger sample 
size of 57,151 women from the UK Biobank from ages 40 to 69 (43), Ge et al. observed that 
fibroid prevalence was very low at 2.77% (43). For example, a study by Baird et al. (2001) 
observed that the cumulative incidence of fibroids to be approximately 70% for white women 
aged 49 years who were systematically screened by ultrasounds. The large discrepancy between 
prevalence estimates between the two studies could signal potential misclassification for fibroid 
controls resulting in a lower heritability estimate in the Ge et al. study.  
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 This was the first estimate of fibroid heritability using a dataset of EA women with 
image-confirmed fibroid status. We observed that fibroid heritability in our study was higher 
than a previous genetic estimate using GWAS data. This result could in part be due to limiting 
our samples to image-confirmed cases and controls. In addition, we observed that our fibroid 
heritability estimate of 33% was not attenuated when censoring genetic loci previously 
associated with fibroid risk. This suggests that many of the genetic loci that are associated with 
fibroid risk in EA women are yet to be discovered. Future studies on fibroid risk are needed to 
understand the genetic underpinnings of fibroid heritability in EA women.   
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Figure 3.1. Estimated heritability of each chromosome by chromosome length in Mb.  
R
2
 is 0.89%, and the p-value of the model is 0.669. 
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Figure 3.2. Estimated heritability of each chromosome by chromosome length in Mb with 
sections of chromosome 8 removed.  
To help all models converge, the model used to produce this figure adjusted for age, BMI, and 7 
PCs with a prevalence estimate at 70%. 
 
 
44 
 
 
Figure 3.3. Proportion of heritability estimates and percentage of SNPs pie charts for SNPs that were partitioned into 
intergenic and genic SNPs.  
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Table 3.1. Demographics table of BioVU European American women. 
Demographic Characteristics N BioVU 
Age (mean±SD) 2,109 50.8±16 
BMI (kg/m
2
) (mean±SD) 2,109 28.6±7 
Fibroid Risk 2,109  
     Control (%) 1,042 49 
     Case (%) 1,067 51 
Fibroid Volume (cm
3
) median (IQR) 373 9.6 (2.3-39.0) 
Largest Fibroid Dimension (cm) median 
(IQR) 
551 2.6 (1.6-4.4) 
BMI-body mass index; kg/m
2
-kilograms per meters squared; cm
3
-cubic centimeters; cm- centimeters; SD-standard 
deviation; IQR-interquartile range. 
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Table 3.2. Heritability estimates for fibroid risk using European Americans within BioVU. 
Outcome  Heritability Estimate ± (Std. Err.) P-value 
Fibroid Risk 
a 
0.33 ± (0.18) 0.040* 
Largest Fibroid Dimension 0.35 ± (0.47) 0.238 
Largest Fibroid Volume 0.14 ± (0.66) 0.417 
Model: Adjusted for age, BMI, and 5 PCs. 
SNPs are limited to ≥5% MAF. 
a: Prevalence estimates of fibroid risk is set at 70%. 
*Statistically significant 
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Table 3.3. Heritability estimates from partitioned SNPs into intergenic and genic regions. 
Location Heritability Estimate ± (Std. Err.) Number of SNPs
a 
Intergenic 0.21 ± 0.15 280 
Genic 0.12 ± 0.14 169 
Model: Adjusted for age, BMI, and 5 PCs. 
SNPs are limited to ≥5% MAF. 
Prevalence estimates of fibroids are set at 70%. 
a: In 10,000 SNPs 
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Table 3.4. Heritability estimates of fibroid risk with suggestive to significant regions of the 
genome removed from prior studies. 
Studies Heritability Estimate ± (Std. Err.) 
No Studies 0.33 ± (0.18) 
Cha et al. (2011) (50) 0.33 ± (0.18) 
Hellwege et al. (2017) (51) 0.33 ± (0.18) 
All Studies (50, 51) 0.34 ± (0.18) 
Model: Adjusted for age, BMI, and 5 PCs. 
SNPs are limited to ≥5% MAF. 
Prevalence estimates of fibroids are set at 70%. 
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CHAPTER 4  
 
ADMIXTURE MAPPING OF UTERINE FIBROID SIZE AND NUMBER IN AFRICAN 
AMERICAN WOMEN 
 
INTRODUCTION 
As discussed in Chapter 1, racial disparities in fibroid risk and characteristics exist. For 
example, in addition to AA women having an approximately two- to three-fold higher risk of 
fibroids when compared to EA women (7), AA women also have more numerous and larger 
fibroids (2). Additionally, AAs are two times more likely than EAs to receive surgical treatments 
for fibroids such as a hysterectomies (8). 
While the heritability of specific fibroid characteristics, such as fibroid size and number, 
is unknown, heritability estimates of fibroid risk from twin studies have ranged between 26% 
and 69% (19, 20). Additional support for genetic etiology for fibroids comes from racial 
differences in fibroid risk (2, 7, 14), as well as well as the racial differences in fibroid size and 
number between AA and EA women. A few studies have shown a direct relationship between 
increasing fibroid size and gene variants (53, 65). Edwards et al. (2013) observed associations 
between increasing fibroid size in EAs with gene variants in TNRC6B and Bet1 golgi vesicular 
membrane trafficking protein like (BET1L) (53) that were originally found in a genome-wide 
association study (GWAS) of fibroid risk (50). Aissani et al. (2015) showed associations 
between fibroid risk and largest fibroid dimension when evaluating a set of candidate gene 
variants (65). 
Admixture mapping is an analytic approach in genetics to evaluate the relationship 
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between genetic ancestry and disease risk. Admixture mapping analyses are performed using 
admixed populations such as AAs where there are known prevalence differences in disease risk 
across racial groups. AA women have on average approximately 80% African ancestry and 20% 
European ancestry (66). Admixture mapping has been successfully applied in studies examining 
multiple sclerosis (67), keloids (68), and prostate cancer (69) in AA populations. A few previous 
studies have performed admixture mapping analyses on fibroid risk using AA individuals (70, 
71). In the first study by Wise et al. (2012), the authors performed an admixture mapping study 
using ultrasound- or image-confirmed 2,453 cases and 2,102 controls with no fibroid diagnosis 
from the prospective cohort, the Black Women’s Health Study, with women throughout the US. 
Using ANCESTRYMAP (72-74) and ADMIXMAP (75), the authors found that the mean 
percentage of African ancestry was significantly higher in fibroid cases when compared to 
controls but did not find a region in the genome that was significantly associated with fibroid risk 
(70). The authors did, however, find suggestive associations in chromosomal regions 2q33, 4p16, 
and, 10q26 (70). In the second admixture mapping study on fibroid risk by Zhang et al. (2015), 
the authors performed a cross-sectional study using 393 ultrasound-confirmed cases and 132 
ultrasound-confirmed controls from the National Institute of Environmental and Health Sciences-
Uterine Fibroid Study. Using ADMIXMAP (75), the authors did not find a significant 
association between global ancestry and fibroid risk. Zhang et al. (2015) did find a region within 
chromosome 1q42.2  with suggestive to significant associations where each African allele 
increased risk after stratifying by BMI (71). In the most recent admixture mapping study by Giri 
et al. (2017), the authors performed a cross-sectional study using AA women from BioVU and 
the CARDIA cohorts. The authors found that BMI interacts with local European ancestry and 
fibroid risk in AA women in two genomic regions, 6p24 and 2q31-31 (76). 
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Fibroids are a heterogeneous disease. Each fibroid characteristic difference, such as 
single versus multiple fibroids or a small versus large fibroid, could be affected by a set of 
genetic loci. A study examining fibroid characteristics might have better power to detect genetic 
determinants of fibroid subphenotypes that might be more closely related to a potential targeted 
treatment than a genetic study on fibroid risk. To the best of our knowledge, no study has 
performed an admixture mapping analysis on fibroid characteristics in AA individuals. The 
objective of this study is to examine the relationship between African ancestry and fibroid 
characteristics, namely size and number. 
 
MATERIALS AND METHODS 
Study Population  
CARDIA Cohort 
The CARDIA cohort was initiated in between 1985 and 1986 with the goal of measuring 
risk factors for coronary heart disease in a cohort of AA and EA individuals (77). The cohort 
consists of 5,115 AA and EA participants between 18 and 30 years of age who were selected 
based on approximately equal proportions of 18 to 24 and 25 to 30 year olds, sex, race (black and 
white), and education status with respect to high school graduation. Cohort recruitment took 
place at four places in the US: Birmingham, AL, Chicago IL, Minneapolis, MN, and Oakland, 
CA (77).  
CARDIA Women’s Study (CWS) is an ancillary study of CARDIA that conducted pelvic 
ultrasounds among women in the CARDIA cohort at 16 years following enrollment. The goal of 
CWS was to evaluate the association between risk factors of polycystic ovary syndrome and 
cardiovascular disease. Largest fibroid dimensions, fibroid number, and other relevant data to 
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our project was collected and recorded by trained CWS research staff (78). A transvaginal 
ultrasound was performed by sonographers who were certified by the American Registry of 
Diagnostic Medical Sonographers (ARMDS) and who had performed at least 50 prior 
transvaginal ultrasound examinations. The sonographers used a 5-7.5 MHz transvaginal probe. 
The dimensions of the largest fibroid were measured and number of fibroids was noted (78). 
Our analyses used lifestyle and sociodemographic information that was collected via self 
and interviewer administered questionnaires (78). Measurements for height and weight were 
collected using a standardized protocol described previously (79). This study was limited to AA 
women with fibroids only. 
BioVU 
The BioVU database was described in Chapter 3. We applied the same phenotyping 
algorithm (21) as was described in Chapter 2, and limited the algorithm to AA individuals only. 
Outcome measurements for analyses include: largest dimension of all fibroid 
measurements, volume of largest fibroid, and number of fibroids (single vs. multiple). To obtain 
an accurate estimate on fibroid volume, we used the following equation to calculate the volume 
of an ellipsoid for both CARDIA and BioVU cohorts: (Length x Width x Height x 0.523). The 
product of the three dimensions was multiplied by 0.523 to estimate volume assuming an 
ellipsoid shape. The total volume measurement and largest dimension were log10 transformed to 
create a normally distributed outcome for regression analysis. Some individuals with volume 
measurements (BioVU - 33.6%) originally had only two measurements for their largest fibroid, 
but we imputed the third measurement by taking the average of the first two measurements.  
The hypothesis of these analyses was that there are different genetic risk factors for 
specific fibroid characteristics, for example you may have a different genetic risk factor for 
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having a larger versus multiple fibroids. Since there are known racial differences in fibroid 
number and size and since race is genetically determined, we evaluated the role of local genetic 
ancestry in risk for specific fibroid characteristics. These analyses are intended to better 
understand racial differences in fibroid phenotypic heterogeneity. Comparing subclasses of cases 
to controls would not necessarily tell us if there are within case subphenotype (fibroid 
characteristics) differences, as evidence of an association from a case-control analysis may still 
be a result of fibroid risk and not risk specific to a fibroid subphenotype. Because of this, the 
individuals in this study are limited to fibroid cases only. This study has been evaluated and 
approved by the VUMC IRB. 
Genotyping 
CARDIA AA participants were genotyped as part of the Candidate Gene Association 
Resource (CARe) study using the Affymetrix 6.0 array (Affymetrix, Santa Clara, CA). BioVU 
AA participants were genotyped using the Affymetrix Axiom Biobank array (Affymetrix, Inc., 
Santa Clara, CA) and on the Axiom World Array 3 platform (Affymetrix, Inc., Santa Clara, CA). 
DNA was purified and quantitated by PicoGreen (Invitrogen, Inc., Grand Island, NY).  
GWAS Quality Control (QC) 
The same QC protocol was performed on both CARDIA and BioVU populations 
separately using PLINK1.7 software (58) and using the reference genome build GRCh37.p13 
(Appendix H, Appendix I). The following steps were taken in our quality control analysis: (1) 
dropped subjects with inconsistent genetic versus reported sex, (2) dropped related subjects, 
meaning all individuals with greater than a 0.95 probability of IBD and only one individual from 
a pair with a probability (IBD) between 0.2 and 0.95, (3) dropped SNPs without chromosomal 
locations, (4) dropped SNPs with a MAF of equal to or less than 1%, (5) dropped SNPs and 
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subjects with low genotyping efficiency (≤95%),  and (6) dropped SNPs with a Hardy-Weinberg 
Equilibrium p-value ≤ 1x10-6. Alleles were aligned to the genomic + strand using the 1000 
Genomes (build 37, 2013). 
Statistical Analyses 
Ancestry Estimation 
Demographic and covariate information were summarized using Stata/SE (College 
Station, Texas). PCs of ancestry were estimated using EIGENSTRAT4.2 (Appendix J, 
Appendix K) (61). Assigning ancestry to SNPs using allele frequencies from the 1,000 Genomes 
Project as proxies to population allele frequencies (Phase 3 1,000 Genomes reference panels) 
(80) was accomplished using LAMP-ANC (Local Ancestry in adMixed Populations - 
ANCestral) (81-83). We used SNPs whose allele frequency difference between African ancestry 
and European ancestry was ≥20% using PLINK1.7 software (58). Local ancestry was estimated 
using the following criteria as input: seven generations since admixture event, recombination rate 
at 1x10
-8
, average ancestry composition per individual at 0.8 for African and 0.2 for European, 
respectively, proportion of overlap between windows of ancestry inference at 0.2, and r-squared 
threshold for LD-pruning at 0.1. Finally, local ancestry was coded as the number of European 
ancestry calls per each locus (0, 1, or 2). Global ancestry (percentage of European ancestry) was 
calculated for each individual by taking the number of European ancestry calls for all markers 
and dividing that number by the total number of ancestry calls. 
Global and Local Ancestry Analyses 
Linear and logistic regression was performed for each outcome for BioVU and CARDIA, 
respectively, using PLINK 1.7 software (58). Outcomes included log10 transformed volume of 
largest fibroid, log10 transformed largest dimension of all fibroids, and number of fibroids (single 
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vs multiple). The exposure included global or local ancestry. Fixed effects inverse-variance 
weighted meta-analysis comparing global or local ancestry across CARDIA and BioVU AAs 
was then performed for each outcome, respectively, using METAL software (84).  
Quantile-quantile (QQ) plots of local ancestry analyses were created for each outcome 
(Appendix L, Appendix M, Appendix N, Appendix O, Appendix P, Appendix Q, Appendix 
R, Appendix S, Appendix T). A p-value of 0.05 or less denoted significance for all analyses 
involving global ancestry. The significance threshold for analyses of local ancestry was 
determined using 10,000 permutation tests for each outcome independently using PLINK1.7 
software (58). The significance threshold for largest fibroid dimension, volume of largest fibroid, 
and fibroid number were determined to be 2.05x10
-5
, 1.98x10
-5
, and 4.80x10
-5
, respectively. The 
suggestive threshold was found by taking two log10 down from the significance threshold. We 
adjusted for age and BMI for all analyses involving global genetic ancestry and adjusted for age, 
BMI, and five PCs for all analyses involving local genetic ancestry. We adjusted for BMI 
because BMI was found to be a confounder in a previous admixture mapping study on fibroid 
risk (71). We also performed admixture mapping analyses between local ancestry and fibroid 
number and volume for the reported admixture mapping peaks without adjustment for BMI and 
note that this did not significantly alter the association signals at these chromosomes (Appendix 
U, Appendix V, Appendix W, Appendix X, Appendix Y, Appendix Z, Appendix AA). We 
also performed local ancestry analysis adjusting for the most significant single SNP association 
within the admixture mapping peak regions in order to identify any genetic/imputed SNPs that 
explain the ancestry peaks.  
Single SNP Association Analyses 
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Non-genotyped SNPs in the suggestive mapping peak regions were imputed, and single 
SNP associations on BioVU and CARDIA were performed for each outcome, respectively. 
Suggestive mapping peak regions were defined as one log10 down from the most significant 
marker in a mapping peak above the suggestive threshold.  
Suggestive peaks were further evaluated for single SNP associations in separate analyses 
by characteristics. A fixed effects inverse-variance weighted meta-analysis was performed 
comparing the single SNP association results across CARDIA and BioVU AAs using METAL 
software (84). The significance threshold for the single SNP association analyses was determined 
by calculating the effective number of independent SNPs among all genotyped SNPs within 
suggestive mapping peak regions of each outcomes, respectively, using simpleM software (85-
87). The significance threshold for fibroid number and volume were determined to be 8.78x10
-6
 
and 5.42x10
-5
, respectively. We adjusted for age, BMI, and five PCs for all analyses involving 
single locus test of association.  
 
RESULTS 
Demographic Data 
 There were 171 AAs in CARDIA and 438 in BioVU with information on fibroid 
characteristics (Table 4.1). The mean age and BMI were similar among AAs in CARDIA (age: 
41.3±4 years; BMI: 33.4±8) and BioVU (age: 41.5±11 years; BMI: 32.9±8), and the majority of 
subjects were obese (BioVU: 60%; CARDIA: 64%). The median volume of largest fibroid and 
largest fibroid dimension was smaller for CARDIA (volume: 5.6 cm
3
; largest dimension: 2.5 cm) 
than for BioVU AAs (volume: vs 19.7 cm
3
; largest dimension: 3.6 cm). Additionally, CARDIA 
AAs were more likely to have multiple fibroids than BioVU AAs (71% vs 58%). Finally, the 
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mean percentage of European ancestry was similar for CARDIA and BioVU AAs (14.9% vs 
15.5%). 
Global Ancestry Analyses 
 We observed a significant association between percentage of European ancestry and 
number of fibroids. A 10% decrease in global European ancestry was significantly associated 
with multiple fibroids (OR: 0.78; 95% CI: 0.66, 0.93; p = 6.05x10
-3
) (Table 4.2). There were no 
significant associations in the meta-analyses between percentage of global European ancestry 
and volume of largest fibroid or largest dimension of all fibroids for BioVU and CARDIA AAs, 
although a 10% decrease in global European ancestry was near significantly associated with 
largest dimension (Beta: -0.029; 95% CI: -0.059, 0.001) (Table 4.2).  
Local Ancestry Analyses 
 We did not observe associations between local ancestry and number of fibroids, volume 
of largest fibroid, or largest dimension of all fibroids that were statistically significant after 
multiple comparisons. We did, however, observe five suggestive associations for number of 
fibroids (p<4.80x10
-3
) and one suggestive association for volume of largest fibroid (p<1.97x10
-3
) 
(Table 4.3). Additionally, there were several statistically significant single SNP associations 
within the admixture mapping regions for number of fibroids and volume of largest fibroid. 
 The most significant admixture mapping signal was seen in number of fibroids within 
10q21.1 near inositol polyphosphate multikinase (IPMK), where each European chromosome 
decreased the odds of multiple fibroids (OR: 0.51; 95% CI: 0.36, 0.74; p = 3.23x10
-4
) (Table 4.3, 
Figure 4.1). The most significant single SNP in this region was rs12219990, where each effect 
allele decreased the odds of multiple fibroids (OR: 0.41; 95% CI: 0.28, 0.60; p = 3.82x10
-6
) 
(Table 4.4). After adjusting for the most significant SNP from the single SNP association 
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analyses, rs12219990, the original admixture mapping signal was reduced (OR: 0.64; 95% CI: 
0.43, 0.94; p = 0.0214) (Table 4.3, Figure 4.1) suggesting the admixture mapping peak was due 
to this SNP. The effect allele for rs12219990 was more common among Europeans (35%) than 
among Africans (7%) (data not shown).   
 There was one suggestive admixture mapping peak in volume of largest fibroid in region 
10q24.1-10q24.32 near leucine zipper tumor suppressor 2 (LZTS2), where each European allele 
decreased the probability of larger of fibroids (beta: -0.23; 95% CI: -0.27, -0.09; p = 1.48x10
-3
) 
(Table 4.3, Appendix BB). The most significant single SNP in this region was rs4919512, 
where each effect allele decreased the probability of larger fibroids (Beta: -0.25; 95% CI: -0.37, -
0.13; p = 2.82x10
-5
) (Table 4.4). After adjusting for the most significant SNP from the single 
SNP association analyses, rs4919512, the original admixture mapping signal was slightly 
reduced (beta: -0.12; 95% CI: -0.27, 0.08; p = 0.145) (Table 4.3, Appendix BB).  
 
DISCUSSION 
 This is the first admixture mapping study to examine the effects that African ancestry has 
on uterine fibroid characteristics. In this study we observed a strong inverse association between 
mean European ancestry and fibroid number, where increasing global African ancestry increases 
the odds of having multiple fibroids. While there were no statistically significant local ancestry 
analyses of any fibroid characteristic, there were multiple suggestive regions of fibroid number 
(Figure 4.1, Appendix CC, Appendix DD, Appendix EE, Appendix FF) and volume 
(Appendix BB). Additionally, there were two statistically significant single SNP associations: 
one on 10q21.1 for fibroid number (rs12219990) and another on 10q24.31 for fibroid volume 
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(rs4919512). Furthermore, the local ancestry analyses highlighted genes with potential biological 
significance in etiology of fibroid characteristics. 
 There were five genes (sin3A association protein 130 [SAP130], proteasome 26S subunit, 
non-ATPase 6 [PSMD6], plexin A4 [PLXNA4], IPMK, and SNW domain containing 1 [SNW1]) 
identified by local ancestry analyses of fibroid number and one gene (LZTS2) identified from our 
analyses of fibroid volume (Table 4.3). Four out of the five genes identified in the fibroid 
number analyses (SAP130, PLXNA4, IPMK, and SNW1) have been previously associated with 
cancer susceptibility or tumor growth (88-91). While the fifth gene (PSMD6) was previously 
associated with delay in DNA repair when depleted (92). The only gene, LZTS2, that was 
identified by our analyses of fibroid volume has also been attributed in many cancers (93) where 
depletion of LZTS2 increases probability of tumorigenesis (94). Further analyses evaluating the 
expression level of these genes in the Genotype-Tissue Expression (GTEx) project database, 
which aims to characterize the relationship between tissue-specific gene expression and genotype 
(95), demonstrated that LZTS2, PSMD6,  SAP130, and SNW1 were expressed (reads per kilobase 
of transcript per million mapped reads [RPKM] > 5) in uterine tissue (GTEx Analysis Release 
V6p (dbGaP Accession phs000424.v6.p1)) (95). Out of 53 tissues in total, LZTS2 was expressed 
more in the uterus than any other tissue. This supports our observed data that genetic variation 
around LZTS2 may decrease gene expression leading to a susceptibility of fibroid tumor growth.  
 We also evaluated potential candidate regions that have been implicated in prior studies 
of fibroids and observed that the region 12q14.1-q14.3 contained a small admixture mapping 
peak associated with fibroid number (p = 7.21x10
-3
) and included HMGA2 (Appendix GG, 
Appendix HH, Appendix II), a gene that was previously implicated in fibroid risk in studies of 
the eker rat. The eker rat represents an animal model that spontaneously forms fibroid tumors 
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similar to that of humans (47). Both the human HMGA2 and eker rat homolog are atypically 
expressed in fibroid tumors (47). The HMGA proteins are part a family of transcription factors 
(47, 96). Progesterone and estrogen receptor activity has been shown to be regulated by the 
HGMA subfamily (47, 97-100).  
 The prior admixture mapping studies by Wise et al. (2012), Zhang et al (2015), and Giri 
et al. (2017) identified several suggestive associations (70, 71, 76); none overlapped with our 
study findings. However, the Wise et al. (2012) global ancestry analyses showed a significant 
inverse association between global European ancestry and fibroid risk (70), consistent with our 
findings suggesting that African ancestry is not only associated with the development of a fibroid 
(or fibroid risk) but with the development of multiple fibroids. The second admixture study by 
Zhang et al. (2015) used 393 AA cases finding no association between global European ancestry 
and fibroid risk (71).  
 A difference between the two prior admixture mapping studies on uterine fibroids (70, 
71) and ours included that our study used GWAS data, allowing us to conduct single SNP 
association analyses within identified regions. Wise et al. (2012) and Zhang et al. (2015) used 
panels of ancestry informative markers.  
 Previous estimations of ancestry place AA individuals having about 20% European 
ancestry and 80% African ancestry (66). The mean percentage of European ancestry for our 
study, however, was 15.5% for BioVU AAs and 14.9% for CARDIA AAs. The lower average 
percentage of European ancestry in our study could be an artifact of enriching for a trait (i.e. 
fibroids) that is more common in AAs (2).  
 There were limitations to our study. Our sample size was modest for each cohort (BioVU 
N=438; CARDIA N=171) matching the cohort size for admixture mapping study by Zhang et al. 
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(2015) (N=525). We, however, performed meta-analyses between BioVU and CARDIA 
individuals which served as a form of replication and validation for our findings. Additionally, 
all fibroid characteristic information was assessed either via ultrasound or surgery leading to a 
decrease in outcome misclassification. In addition, we did not perform subanalyses limiting to 
either image- or surgery-confirmed fibroid cases since all CARDIA individuals in this study had 
only ultrasounds to assess fibroid characteristics and since only some BioVU individuals had this 
information recorded during the abstraction process. It could be possible that BioVU individuals 
whose fibroids were discovered during surgery had a different tumor characteristic profile than 
women whose fibroids were confirmed via ultrasounds which could introduce bias in the 
analyses. Including women who had surgery could possibly inflate the effect sizes since these 
women may be more likely to have severe symptoms that may be due to larger size and/or 
number of fibroids. Finally, there is no overlap between the previous two previous admixture 
mapping studies on fibroid risk using AAs (70, 71) and our study. This could be because our 
study examined genetic risk factors via ancestry for differences in fibroid size and number and 
that these genetic factors via ancestry differ from the genetic factors for fibroid incidence.  
 Our study was the first admixture mapping study to access the association between 
ancestry and fibroid characteristics using AA populations. We found that global ancestry 
influences the number of fibroids and found many suggestive mapping peaks influencing fibroid 
number and one mapping peak influencing fibroid volume. Further studies needs to be performed 
to understand the biological mechanisms underlying the observed genetic associations. 
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Figure 4.1. Admixture mapping analysis of chromosome 10 with overlapping single SNP 
association analysis results. 
The X-axis indicates the genomic position along chromosome 10 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs12219990; dashed green line – conditioned on rs12219990) with fibroid 
number (single vs multiple) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, 5 PCs. The solid green line represents the significance threshold. The solid blue line 
represents the suggestive threshold. The bottom portion of the Y-axis indicates the log10(p value) 
for the single SNP association analyses (blue circles indicates genotyped SNPs; red circles 
indicates imputed SNPs) with fibroid number (single vs multiple) as the outcome. The imputed 
region was found by taking 1 –log down from the most significant mapping peak above the 
suggest threshold. The imputed region encompassed 56,258,202 to 59,854,651 bp. The single 
SNP association analysis was adjusted for age, BMI, and 5 PCs. The SNP, rs12219990, was 
imputed (BioVU info score – 0.921; CARDIA info score – 0.922). The dotted red line represents 
the significance threshold.  
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Table 4.1. Demographics of CARDIA and BioVU African Americans. 
Demographic Characteristics N 
All 
(N=609) 
BioVU  
(N=438) 
CARDIA 
(N=171) 
Age (mean±SD) 609 41.4±9 41.5±11 41.3±4 
BMI (kg/m2) (mean±SD) 606 33.1±8 32.9±8 33.4±8 
     Underweight (<18.5) (%) 6 1 1 1 
     Normal weight (18.5-24.9) (%) 87 14 16 11 
     Overweight (25-29.9) (%) 142 23 23 24 
     Obese (≥30) (%) 371 61 60 64 
Fibroid Volume (cm
3
) median (IQR) 492 14.1 (3.6-47.2) 19.6 (5.3-76.0) 5.6 (2.1-19.3) 
Largest Fibroid Dimension (cm) median 
(IQR) 
562 3.1 (2.0-5.0) 3.5 (2.2-5.7) 2.5 (1.8-3.7) 
Fibroid Number 588    
     1 (%) 226 38 42 29 
     >1 (%) 362 62 58 71 
Percentage of European Ancestry 
(mean±SD) 
609 15.3±10 15.5±10 14.9±10 
BMI-body mass index; kg/m
2
-kilograms per meters squared; cm
3
-cubic centimeters; cm- centimeters; SD-standard 
deviation; IQR-interquartile range. 
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Table 4.2. Associations between exposure of mean percentage of European ancestry and 
outcome. 
Number of Fibroids 
b 
Cohort Adjusted OR [95% CI] 
a
 
BioVU 0.77 [0.62, 0.94]* 
CARDIA  0.83 [0.59, 1.16] 
Meta-analysis 0.78 [0.66, 0.93]** 
Volume of Largest Fibroid 
c 
Cohort Adjusted Beta [95% CI] 
a 
BioVU -0.043 [-0.137, 0.052] 
CARDIA 0.022 [-0.081, 0.126] 
Meta-analysis -0.013 [-0.082, 0.056] 
Largest Dimension of All Fibroids 
d 
Cohort Adjusted Beta [95% CI] 
a 
BioVU -0.029 [-0.059, 0.001] 
CARDIA 0.009 [-0.024, 0.043] 
Meta-analysis -0.012 [-0.034, 0.011] 
a Adjusted for age and BMI; 
b Number is coded as single vs multiple fibroids; 
c Volume is coded as log10 transformed largest fibroid volume in cm
3
; 
d Largest Dimension is coded as log10 transformed largest fibroid dimension of all fibroid measurements in cm; 
* p<0.05, **p<0.007; 
Exposure is in 10% increments of mean percentage of European ancestry; OR-odds ratio; CI-confidence interval; p-
p-value, cm
3
-cubic centimeters; cm- centimeters. 
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Table 4.3. Admixture mapping for number of fibroids and volume of largest fibroid in 
African American women. 
Number 
c 
10q21.1 
Nearby Gene Cohort OR [95% CI]
 a 
p
 a
 OR [95% CI]
 b
 p
 b
 
IPMK 
BioVU 0.54 [0.62, 1.44] 3.36x10
-3
 0.68 [0.44, 1.04] 0.0764 
CARDIA 0.41 [0.18, 0.92] 0.030 0.50 [0.21, 1.17] 0.110 
Meta-analysis 0.51 [0.36, 0.74] 3.23x10
-4
 0.64 [0.43, 0.94] 0.0214 
14q24.2-14q24.3 
Nearby Gene Cohort OR [95% CI]
 a
 p
 a
 OR [95% CI]
 b
 p
 b
 
SNW1 
BioVU 2.07 [1.34, 3.18] 9.89x10
-4
 1.81 [1.17, 2.82] 8.12x10
-3
 
CARDIA 1.62 [0.74, 3.55] 0.226 1.54 [0.69, 3.44] 0.289 
Meta-analysis 1.95 [1.34, 2.85] 5.25x10
-4
 1.75 [1.19, 2.57] 4.66x10
-3
 
2q14.3-2q21.1 
Nearby Gene Cohort OR [95% CI]
 a
 p
 a
 OR [95% CI]
 b
 p
 b
 
SAP130 
BioVU 0.64 [0.43, 0.95] 0.026 0.74 [0.48, 1.13] 0.163 
CARDIA 0.47 [0.24, 0.93] 0.030 0.85 [0.37, 1.96] 0.701 
Meta-analysis 0.59 [0.42, 0.83] 2.60x10
-3
 0.76 [0.52, 1.11] 0.157 
7q32.2-7q33 
Nearby Gene Cohort OR [95% CI]
 a
 p
 a
 OR [95% CI]
 b
 p
 b
 
PLXNA4 
BioVU 2.02 [1.33, 3.08] 1.05x10
-3
 1.85 [1.20, 2.86] 5.70x10
-3
 
CARDIA 1.02 [0.46, 2.25] 0.964 0.51 [0.20, 1.27] 0.149 
Meta-analysis 1.74 [1.20, 2.52] 3.54x10
-3
 1.46 [0.98, 2.16] 0.0604 
3p14.2-3p14.1 
Nearby Gene Cohort OR [95% CI]
 a
 p
 a
 OR [95% CI]
 b
 p
 b
 
PSMD6 
BioVU 1.56 [1.01, 2.40] 0.045 1.45 [0.94, 2.25] 0.095 
CARDIA 2.96 [1.25, 7.05]
 
0.014 2.23 [0.92, 5.37] 0.074 
Meta-analysis 1.77 [1.20, 2.60] 3.86x10
-3
 1.58 [1.07, 2.34] 0.022 
Volume 
d 
10q24.1-10q24.32 
Nearby Gene Cohort Beta [95% CI] 
a
 p 
a
 Beta [95% CI] 
b
 p 
b
 
LZTS2 
BioVU -0.26 [-0.43, -0.08] 4.62x10
-3
 -0.16 [-0.35, 0.04] 0.116 
CARDIA -0.18 [-0.42, 0.06] 0.138 -0.04 [-0.30, 0.22] 0.754 
Meta-analysis -0.23 [-0.27, -0.09] 1.48x10
-3
 -0.12 [-0.27, 0.08] 0.145 
a Model 1: Adjusted for age, BMI, and 5 PCs; 
b Model 2: Adjusted for age, BMI, and 5 PCs + adjustment for most significant single SNP; 
c Number is coded as single vs multiple fibroids; 
d Volume is coded as log10 transformed largest fibroid volume in cm
3
; 
OR-odds ratio; CI-confidence interval; p-p-value; cm
3
-cubic centimeters. 
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Table 4.4. Single SNP signals in admixture mapping regions for number of fibroids and 
volume of largest fibroid in African American women. 
Number 
b 
rs12219990 in 10q21.1* 
Cohort OR [95% CI]
 a
 p EA/RA BioVU/CARDIA EAF 
BioVU 0.41 [0.27, 0.63] 3.29x10
-5
 C/A 0.14/0.11 
CARDIA 0.39 [0.15, 0.97] 0.042   
Meta-analysis 0.41 [0.28, 0.60] 
a
 3.82x10
-6
   
rs11394508 in 14q24.2-14q24.3 
Cohort OR [95% CI]
 a
 p EA/RA BioVU/CARDIA EAF 
BioVU 0.50 [0.37, 0.68] 6.02x10
-6
 CA/C 0.37/0.37 
CARDIA 0.80 [ 0.46, 1.36] 0.402   
Meta-analysis 0.56 [0.43, 0.73] 1.29x10
-5
   
rs6723563 in 2q14.3-2q21.1 
Cohort OR [95% CI]
 a
 p EA/RA BioVU/CARDIA EAF 
BioVU 0.52 [0.31, 0.88] 0.015 A/G 0.09/0.07 
CARDIA 0.15 [0.06, 0.40] 1.41x10
-4
   
Meta-analysis 0.40 [0.25, 0.63] 7.68x10
-5
   
rs782525 in 7q32.2-7q33 
Cohort OR [95% CI]
 a
 p EA/RA BioVU/CARDIA EAF 
BioVU 1.47 [1.07, 2.01] 0.017 G/A 0.27/0.27 
CARDIA 2.50 [1.48, 4.24] 6.39x10
-4
   
Meta-analysis 1.69 [1.29, 2.21] 1.43x10
-4
   
rs112428319 in 3p14.2-3p14.1 
Cohort OR [95% CI]
 a
 p EA/RA BioVU/CARDIA EAF 
BioVU 0.40 [0.21, 0.05] 8.01x10
-3
 G/A 0.05/0.06 
CARDIA 0.14 [0.79, 0.41] 3.59x10
-4
   
Meta-analysis 0.30 [0.17, 0.53] 3.74x10
-5
   
Volume 
c 
rs4919512 in 10q24.1-10q24.32* 
Cohort Beta [95% CI] 
a
 p EA/RA BioVU/CARDIA EAF 
BioVU -0.25 [-0.40, -0.10] 8.16x10
-4
 C/T 0.29/0.22 
CARDIA -0.25 [-0.45, -0.06] 0.012   
Meta-analysis -0.25 [-0.37, -0.13] 2.82x10
-5
   
a Model 1: Adjusted for age, BMI, and 5 PCs; 
b Number is coded as single vs multiple fibroids; 
c Volume is coded as log10 transformed largest fibroid volume in cm
3
; 
*significant meta-analysis after correction for multiple testing  
OR-odds ratio; CI-confidence interval; p-p-value; EA-effect allele; RA-reference allele; EAF-
effect allele frequency; cm
3
-cubic centimeters.  
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CHAPTER 5  
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 
 The experiments described in this dissertation aimed to highlight epidemiologic and 
genetic risk factors for uterine fibroid characteristics, namely number and size, as well as to 
estimate fibroid heritability of uterine fibroids. Most studies on fibroids focus on fibroid 
presence. Part of the reason for the lack of research on fibroid characteristics is the requirement 
of each patient to be systematically screened via ultrasounds or surgeries to measure and count 
fibroids. By using datasets within BioVU and CARDIA, we were able to perform a large scale 
epidemiologic analysis on fibroid characteristics, to perform the first GWAS and admixture 
mapping analysis on fibroid characteristics to scan the genome for associations with fibroid 
number and size, and to estimate and characterize fibroid heritability.  
 
 The aim of Chapter 2 was to evaluate physical and clinical features of women with 
fibroids in relation to selected fibroid characteristics. Using a dataset of patient EHRs from the 
Synthetic Derivative consisting of 2,302 women with image- or surgery-confirmed fibroids, we 
performed the largest association analyses between fibroid risk factors and fibroid 
characteristics. The fibroid risk factors included age, BMI, race (black or white), type 2 diabetes 
status, and number of living children (proxy to parity) and were abstracted from patient EHRs. 
The outcomes included fibroid number (single vs. multiple), volume, and largest dimension, 
which were manually abstracted of patient image- or surgery-reports. After observing no effect 
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modification by race in analyses of age, we observed that increasing age was associated with 
multiple and larger fibroids and that this effect changes nonlinearly with age. In addition, we 
observed that black race was associated with both multiple and larger fibroids. We observed no 
associations between fibroid characteristics and BMI or type 2 diabetes. These findings suggest 
that physical and clinical features of a woman may help to determine if and when she is at risk of 
developing fibroids with specific characteristics. These results could help pave the way towards 
the best route of fibroid treatment. 
 
 In Chapter 3, we were the first to estimate and characterize the heritability of fibroids 
using a dataset of 2,109 EA women from BioVU with image-confirmed fibroid status. We 
estimated heritability of fibroid risk was 0.33, being much higher than previous genetic estimates 
on fibroid heritability of approximately 9%. In addition, we observed that our fibroid heritability 
estimate of 33% was not attenuated when censoring genetic loci previously associated with 
fibroid risk. This suggests that many of the genetic loci that are associated with fibroid risk in EA 
women have yet to be discovered. We observed that fibroid heritability was not evenly 
distributed throughout the genome. Chromosome 8 was the most heritable chromosome, with 
most of the heritability of chromosome 8 being in 8q. Lastly, there was no enrichment of fibroid 
heritability for intergenic or genic regions.  
 
 The aim of Chapter 4 was to evaluate the relationship between genetic ancestry and 
uterine fibroid characteristics. We performed the first admixture mapping study to examine the 
effects that African ancestry has on uterine fibroid characteristics using 609 AA women from 
BioVU and CARDIA. In this study we observed a strong significant inverse association between 
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mean European ancestry and fibroid number, where increasing global African ancestry increases 
the odds of having multiple fibroids. While there were no statistically significant local ancestry 
analyses of any fibroid characteristic, there were six suggestive regions of fibroid number and 
volume. Additionally, there were two statistically significant single SNP associations within the 
admixture mapping peaks: one on 10q21.1 for fibroid number (rs12219990) and another on 
10q24.31 for fibroid volume (rs4919512).  
 
Future Directions 
 
 These Chapters explored the epidemiologic and genetic risk factors of uterine fibroid 
characteristics using a mixture of prospective cohort data (CARDIA) and de-identified EHRs 
(Synthetic Derivative and BioVU).  Epidemiologic and genetic data from the Synthetic 
Derivative and BioVU is an invaluable resource. In particular, by using this resource we 
successfully performed the largest epidemiologic analyses of uterine fibroid characteristics using 
data from 2,302 individuals. There are some difficulties with handling this rich data resource. 
This includes the variable abstraction process. All the EHRs include digitalized hospital notes 
which can vary greatly depending on the nurse or physician recording the information. In 
addition, there was human error where information within a single patient’s record was 
sometimes inconsistent. In studies that use this new resource consisting of patient EHRs, there 
needs to be credence that large sample sizes will be needed to offset of loss of power due to 
minor misclassification of data. 
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 This study also performed the first admixture mapping analysis on fibroid characteristics. 
We observed many genetic association with fibroid size and number that were not associated 
previously associated with fibroid risk. This suggests that different genetic etiologies might exist 
between fibroid size and number and fibroid risk. Further genetic studies are needed to explore 
the underlying mechanisms observed in these genetic associations. 
 
 Lastly, we estimated the heritability of fibroids in a population of EA women with image-
confirmed fibroid status. We observed that chromosome 8q explained the greatest proportion of 
variance for fibroid risk along with chromosomes 11 and 10. In addition, after censoring loci 
previously implicated with fibroid risk in populations of Japanese and AA women, there was no 
attenuation fibroid heritability. This entails that there are many genetic loci that increase fibroid 
risk in EA women that have yet to be discovered. Future genetic studies on fibroid risk are 
needed to understand fibroid heritability in EA women.  
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APPENDICES 
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Appendix A. Final SNP count for each outcome. 
Outcome Sample Size Post QC SNP Number - MAF 5% 
Fibroid Risk  4,500,362* 
     Case 1,075  
     Control 1,059  
Volume 375 4,522,829* 
Max Dimension 554 4,518,340* 
*Post QC SNP Numbers - These are slightly different between studies because we removed SNPs out of 
HWE at the end for each outcome independently.  
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Appendix B. Principal Components Plot of BioVU EAs with Reference Population before 
Pruning Outliers. 
AFR-African; AMR-Ad Mixed American; EAS-East Asian; SAS-South Asian; EUR-European. 
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Appendix C. Principal Components Plot of BioVU EAs with Reference Population after 
Pruning Outliers.  
AFR-African; AMR-Ad Mixed American; EAS-East Asian; SAS-South Asian; EUR-European. 
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Appendix D. Heritability estimates for fibroid risk using European Americans within 
BioVU. 
Heritability Estimate ± (Std. Err.) P-value Prevalence 
0.24 ± (0.13) 0.040* 0.10 
0.29 ± (0.16) 0.040* 0.20 
0.33 ± (0.18) 0.040* 0.30 
0.35 ± (0.19) 0.040* 0.40 
0.35 ± (0.20) 0.040* 0.50 
0.35 ± (0.19) 0.040* 0.60 
0.33 ± (0.18) 0.040* 0.70 
0.29 ± (0.16) 0.040* 0.80 
0.24 ± (0.13) 0.040* 0.90 
Model: Adjusted for age, BMI, and 5 PCs. 
SNPs are limited to ≥5% MAF. 
*Statistically significant 
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Appendix E. Heritability estimates for fibroid risk using European Americans within 
BioVU. 
Heritability Estimate ± (Std. 
Err.) 
P-value PC Adjustments 
0.38 ± (0.18) 0.013* 0 
0.34 ± (0.18) 0.031* 1 
0.35 ± (0.18) 0.027* 2 
0.33 ± (0.18) 0.037* 3 
0.33 ± (0.18) 0.038* 4 
0.33 ± (0.18) 0.040* 5 
0.33 ± (0.18) 0.040* 6 
0.29 ± (0.18) 0.064 7 
0.29 ± (0.18) 0.058 8 
0.30 ± (0.18) 0.053 9 
0.30 ± (0.18) 0.056 10 
Model: Adjusted for age and BMI and noted PC number in table. 
SNPs are limited to ≥5% MAF. 
Prevalence estimates of fibroids are set at 70%. 
*Statistically significant 
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Appendix F. Heritability estimates for largest fibroid dimension using European 
Americans within BioVU. 
Heritability Estimate ± (Std. Err.) P-value PC Adjustments 
0.34 ± (0.47) 0.246 0 
0.40 ± (0.47) 0.209 1 
0.40 ± (0.47) 0.209 2 
0.40 ± (0.47) 0.209 3 
0.39 ± (0.47) 0.212 4 
0.35 ± (0.47) 0.238 5 
0.36 ± (0.48) 0.233 6 
0.38 ± (0.48) 0.224 7 
0.39 ± (0.48) 0.214 8 
0.43 ± (0.48) 0.195 9 
0.44 ± (0.48) 0.190 10 
Model: Adjusted for age and BMI and noted PC number in table. 
SNPs are limited to ≥5% MAF. 
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Appendix G. Heritability estimates for largest fibroid volume using European Americans 
within BioVU. 
Heritability Estimate ± (Std. Err.) P-value PC Adjustments 
0.12 ± (0.65) 0.426 0 
0.18 ± (0.65) 0.391 1 
0.18 ± (0.65) 0.389 2 
0.12 ± (0.66) 0.427 3 
0.13 ± (0.66) 0.423 4 
0.14 ± (0.66) 0.417 5 
0.16 ± (0.65) 0.404 6 
0.17 ± (0.67) 0.399 7 
0.24 ± (0.67) 0.355 8 
0.28 ± (0.67) 0.334 9 
0.35 ± (0.67) 0.300 10 
Model: Adjusted for age and BMI and noted PC number in table. 
SNPs are limited to ≥5% MAF. 
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Appendix H. Quality control flowchart of CARDIA AA. 
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Appendix I. Quality control flowchart of BioVU AA. 
 
  
81 
 
 
Appendix J. Graph of the principal component analysis of CARDIA AA cases plotted with 
individuals from the 1,000 Genomes Project. 
AMR-Ad Mixed American; EAS-East Asian; EUR-European; SAS-South Asian. ACB-African 
Caribbeans in Barbados; ASW-Americans of African Ancestry in SW USA; AFR-African. 
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Appendix K. Graph of the principal component analysis of BioVU AA cases plotted with 
individuals from the 1,000 Genomes Project. 
AMR-Ad Mixed American; EAS-East Asian; EUR-European; SAS-South Asian. ACB-African 
Caribbeans in Barbados; ASW-Americans of African Ancestry in SW USA; AFR-African. 
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Appendix L. The QQ plot for the meta-analysis of the admixture mapping results for 
fibroid number (single vs multiple) between BioVU and CARDIA AAs. 
The regression analyses were adjusted for age, BMI, five PCs. Markers with a MAF of at least 
5% were used in the admixture mapping analysis.  
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Appendix M. The QQ plot for the admixture mapping results for fibroid number (single vs 
multiple) for BioVU AAs. 
The regression analyses were adjusted for age, BMI, five PCs. Markers with a MAF of at least 
5% were used in the admixture mapping analysis.  
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Appendix N. The QQ plot for the admixture mapping results for fibroid number (single vs 
multiple) for CARDIA AAs. 
The regression analyses were adjusted for age, BMI, five PCs. Markers with a MAF of at least 
5% were used in the admixture mapping analysis.  
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Appendix O. The QQ plot for the meta-analysis of the admixture mapping results for log10 
transformed volume of largest fibroid between BioVU and CARDIA AAs. 
The regression analyses were adjusted for age, BMI, five PCs. Markers with a MAF of at least 
5% were used in the admixture mapping analysis.  
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Appendix P. The QQ plot for the admixture mapping results for log10 transformed volume 
of largest fibroid for BioVU AAs. 
The regression analyses were adjusted for age, BMI, five PCs. Markers with a MAF of at least 
5% were used in the admixture mapping analysis.  
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Appendix Q. The QQ plot for the admixture mapping results for log10 transformed volume 
of largest fibroid for CARDIA AAs. 
The regression analyses were adjusted for age, BMI, five PCs. Markers with a MAF of at least 
5% were used in the admixture mapping analysis.  
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Appendix R. The QQ plot for the meta-analysis of the admixture mapping results for log10 
transformed largest dimension of all fibroids between BioVU and CARDIA AAs. 
The regression analyses were adjusted for age, BMI, five PCs. Markers with a MAF of at least 
5% were used in the admixture mapping analysis. 
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Appendix S. The QQ plot for the admixture mapping results for log10 transformed largest 
dimension of all fibroids for BioVU AAs. 
The regression analyses were adjusted for age, BMI, five PCs. Markers with a MAF of at least 
5% were used in the admixture mapping analysis. 
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Appendix T. The QQ plot for the admixture mapping results for log10 transformed largest 
dimension of all fibroids for CARDIA AAs. 
The regression analyses were adjusted for age, BMI, five PCs. Markers with a MAF of at least 
5% were used in the admixture mapping analysis.  
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Appendix U. Admixture mapping analysis of chromosome 10 with overlapping single SNP 
association analysis results with and without adjustment for BMI. 
The X-axis indicates the genomic position along chromosome 10 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs12219990; dashed green line – conditioned on rs12219990) with fibroid 
number (single vs multiple) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, five PCs. The solid orange line represents the admixture mapping analysis that was 
adjusted for age and five PCs only. The solid green line represents the significance threshold. 
The solid blue line represents the suggestive threshold. The bottom portion of the Y-axis 
indicates the log10(p value) for the single SNP association analyses (blue circles indicates 
genotyped SNPs; red circles indicates imputed SNPs) with fibroid number (single vs multiple) as 
the outcome. The imputed region was found by taking 1 –log down from the most significant 
mapping peak above the suggest threshold. The imputed region encompassed 56,258,202 to 
59,854,651 bp. The single SNP association analysis was adjusted for age, BMI, and five PCs. 
The SNP, rs12219990, was imputed (BioVU info score – 0.921; CARDIA info score – 0.922). 
The dotted red line represents the significance threshold.  
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Appendix V. Admixture mapping analysis of chromosome 14 with overlapping single SNP 
association analysis results with and without adjustment for BMI. 
The X-axis indicates the genomic position along chromosome 14 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs11394508; dashed green line – conditioned on rs11394508) with fibroid 
number (single vs multiple) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, five PCs. The solid orange line represents the admixture mapping analysis that was 
adjusted for age and five PCs only.  The solid green line represents the significance threshold. 
The solid blue line represents the suggestive threshold. The bottom portion of the Y-axis 
indicates the log10(p value) for the single SNP association analyses (blue circles indicates 
genotyped SNPs; red circles indicates imputed SNPs) with fibroid number (single vs multiple) as 
the outcome. The imputed region was found by taking 1 –log down from the most significant 
mapping peak above the suggest threshold. The imputed region encompassed 72,802,666 to 
79,205,619 bp. The single SNP association analysis was adjusted for age, BMI, and five PCs. 
The SNP, rs11394508, was imputed (BioVU info score – 0.995; CARDIA info score – 0.956). 
The dotted red line represents the significance threshold.  
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Appendix W. Admixture mapping analysis of chromosome 2 with overlapping single SNP 
association analysis results with and without adjustment for BMI. 
The X-axis indicates the genomic position along chromosome 2 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs6723563; dashed green line – conditioned on rs6723563) with fibroid 
number (single vs multiple) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, five PCs. The solid orange line represents the admixture mapping analysis that was 
adjusted for age and five PCs only. The solid green line represents the significance threshold. 
The solid blue line represents the suggestive threshold. The bottom portion of the Y-axis 
indicates the log10(p value) for the single SNP association analyses (blue circles indicates 
genotyped SNPs; red circles indicates imputed SNPs) with fibroid number (single vs multiple) as 
the outcome. The imputed region was found by taking 1 –log down from the most significant 
mapping peak above the suggest threshold. The imputed region encompassed 123,221,985 to 
131,110,097 bp. The single SNP association analysis was adjusted for age, BMI, and five PCs. 
The SNP, rs6723563, was imputed (BioVU info score – 0.932; CARDIA info score – 0.885). 
The dotted red line represents the significance threshold.  
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Appendix X. Admixture mapping analysis of chromosome 7 with overlapping single SNP 
association analysis results with and without adjustment for BMI. 
The X-axis indicates the genomic position along chromosome 7 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs782525; dashed green line – conditioned on rs7872525) with fibroid 
number (single vs multiple) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, five PCs. The solid orange line represents the admixture mapping analysis that was 
adjusted for age and five PCs only. The solid green line represents the significance threshold. 
The solid blue line represents the suggestive threshold. The bottom portion of the Y-axis 
indicates the log10(p value) for the single SNP association analyses (blue circles indicates 
genotyped SNPs; red circles indicates imputed SNPs) with fibroid number (single vs multiple) as 
the outcome. The imputed region was found by taking 1 –log down from the most significant 
mapping peak above the suggest threshold. The imputed region encompassed 129,822,797 to 
134,670,462 bp. The single SNP association analysis was adjusted for age, BMI, and five PCs. 
The SNP, rs782525, was imputed (BioVU info score – 0.999; CARDIA info score – 0.985). The 
dotted red line represents the significance threshold.  
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Appendix Y. Admixture mapping analysis of chromosome 3 with overlapping single SNP 
association analysis results with and without adjustment for BMI. 
The X-axis indicates the genomic position along chromosome 3 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs112428319; dashed green line – conditioned on rs112428319) with 
fibroid number (single vs multiple) as the outcome. The admixture mapping analysis was 
adjusted for age, BMI, five PCs. The solid orange line represents the admixture mapping analysis 
that was adjusted for age and five PCs only. The solid green line represents the significance 
threshold. The solid blue line represents the suggestive threshold. The bottom portion of the Y-
axis indicates the log10(p value) for the single SNP association analyses (blue circles indicates 
genotyped SNPs; red circles indicates imputed SNPs) with fibroid number (single vs multiple) as 
the outcome. The imputed region was found by taking 1 –log down from the most significant 
mapping peak above the suggest threshold. The imputed region encompassed 63,405,151 to 
66,558,036 bp. The single SNP association analysis was adjusted for age, BMI, and five PCs. 
The SNP, rs112428319, was imputed (BioVU info score – 0.9998; CARDIA info score – 0.994). 
The dotted red line represents the significance threshold.  
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Appendix Z. Admixture mapping analysis of chromosome 10 with overlapping single SNP 
association analysis results with and without adjustment for BMI. 
The X-axis indicates the genomic position along chromosome 10 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs4919512; dashed green line – conditioned on rs4919512) with fibroid 
volume (log10 transformed) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, five PCs. The solid orange line represents the admixture mapping analysis that was 
adjusted for age and five PCs only. The solid green line represents the significance threshold. 
The solid blue line represents the suggestive threshold. The bottom portion of the Y-axis 
indicates the log10(p value) for the single SNP association analyses (blue circles indicates 
genotyped SNPs; red circles indicates imputed SNPs) with fibroid volume (log10 transformed) as 
the outcome. The imputed region was found by taking 1 –log down from the most significant 
mapping peak above the suggest threshold. The imputed region encompassed 98,747,114 to 
103,009,908 bp. The single SNP association analysis was adjusted for age, BMI, and five PCs. 
The SNP, rs4919512, was genotyped for BioVU but imputed for CARDIA (BioVU info score – 
1; CARDIA info score – 0.801). The dotted red line represents the significance threshold. 
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Appendix AA. Admixture mapping analysis of chromosome 12 with overlapping single 
SNP association analysis results with and without adjustment for BMI. 
The X-axis indicates the genomic position along chromosome 10 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs2575289 or rs56133667; dashed teal line – conditioned on rs2575289; 
dashed yellow line - conditioned on rs56133667; dashed purple line - conditioned on rs2575289 
and rs56133667) with fibroid number (single vs multiple) as the outcome. The admixture 
mapping analysis was adjusted for age, BMI, five PCs. The solid orange line represents the 
admixture mapping analysis that was adjusted for age and five PCs only. The solid green line 
represents the significance threshold. The solid blue line represents the suggestive threshold. The 
bottom portion of the Y-axis indicates the log10(p value) for the single SNP association analyses 
(blue circles indicates genotyped SNPs; red circles indicates imputed SNPs) with fibroid number 
(single vs multiple) as the outcome. The imputed region was found by taking 1 –log down from 
the most significant mapping peak above the suggest threshold. The imputed region 
encompassed 61,300,873 to 67,610,913 bp. The single SNP association analysis was adjusted for 
age, BMI, and five PCs. The SNP, rs2575289, was imputed (BioVU info score – 0.976; 
CARDIA info score – 0.991). The SNP, rs56133667, was imputed (BioVU info score > 0.999; 
CARDIA info score > 0.999).  The dotted red line represents the significance threshold of the 
single SNP association analysis.  
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Appendix BB. Admixture mapping analysis of chromosome 10 with overlapping single SNP 
association analysis results. 
The X-axis indicates the genomic position along chromosome 10 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs4919512; dashed green line – conditioned on rs4919512) with fibroid 
volume (log10 transformed) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, five PCs. The solid green line represents the significance threshold. The solid blue line 
represents the suggestive threshold. The bottom portion of the Y-axis indicates the log10(p value) 
for the single SNP association analyses (blue circles indicates genotyped SNPs; red circles 
indicates imputed SNPs) with fibroid volume (log10 transformed) as the outcome. The imputed 
region was found by taking 1 –log down from the most significant mapping peak above the 
suggest threshold. The imputed region encompassed 98,747,114 to 103,009,908 bp. The single 
SNP association analysis was adjusted for age, BMI, and five PCs. The SNP, rs4919512, was 
genotyped for BioVU but imputed for CARDIA (BioVU info score – 1; CARDIA info score – 
0.801). The dotted red line represents the significance threshold.  
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Appendix CC. Admixture mapping analysis of chromosome 14 with overlapping single 
SNP association analysis results. 
The X-axis indicates the genomic position along chromosome 14 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs11394508; dashed green line – conditioned on rs11394508) with fibroid 
number (single vs multiple) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, five PCs. The solid green line represents the significance threshold. The solid blue line 
represents the suggestive threshold. The bottom portion of the Y-axis indicates the log10(p value) 
for the single SNP association analyses (blue circles indicates genotyped SNPs; red circles 
indicates imputed SNPs) with fibroid number (single vs multiple) as the outcome. The imputed 
region was found by taking 1 –log down from the most significant mapping peak above the 
suggest threshold. The imputed region encompassed 72,802,666 to 79,205,619 bp. The single 
SNP association analysis was adjusted for age, BMI, and five PCs. The SNP, rs11394508, was 
imputed (BioVU info score – 0.995; CARDIA info score – 0.956). The dotted red line represents 
the significance threshold.  
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Appendix DD. Admixture mapping analysis of chromosome 2 with overlapping single SNP 
association analysis results. 
The X-axis indicates the genomic position along chromosome 2 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs6723563; dashed green line – conditioned on rs6723563) with fibroid 
number (single vs multiple) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, five PCs. The solid green line represents the significance threshold. The solid blue line 
represents the suggestive threshold. The bottom portion of the Y-axis indicates the log10(p value) 
for the single SNP association analyses (blue circles indicates genotyped SNPs; red circles 
indicates imputed SNPs) with fibroid number (single vs multiple) as the outcome. The imputed 
region was found by taking 1 –log down from the most significant mapping peak above the 
suggest threshold. The imputed region encompassed 123,221,985 to 131,110,097 bp. The single 
SNP association analysis was adjusted for age, BMI, and five PCs. The SNP, rs6723563, was 
imputed (BioVU info score – 0.932; CARDIA info score – 0.885). The dotted red line represents 
the significance threshold.  
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Appendix EE. Admixture mapping analysis of chromosome 3 with overlapping single SNP 
association analysis results. 
The X-axis indicates the genomic position along chromosome 3 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs112428319; dashed green line – conditioned on rs112428319) with 
fibroid number (single vs multiple) as the outcome. The admixture mapping analysis was 
adjusted for age, BMI, five PCs. The solid green line represents the significance threshold. The 
solid blue line represents the suggestive threshold. The bottom portion of the Y-axis indicates the 
log10(p value) for the single SNP association analyses (blue circles indicates genotyped SNPs; 
red circles indicates imputed SNPs) with fibroid number (single vs multiple) as the outcome. The 
imputed region was found by taking 1 –log down from the most significant mapping peak above 
the suggest threshold. The imputed region encompassed 63,405,151 to 66,558,036 bp. The single 
SNP association analysis was adjusted for age, BMI, and five PCs. The SNP, rs112428319, was 
imputed (BioVU info score – 0.9998; CARDIA info score – 0.994). The dotted red line 
represents the significance threshold.  
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Appendix FF. Admixture mapping analysis of chromosome 7 with overlapping single SNP 
association analysis results. 
The X-axis indicates the genomic position along chromosome 7 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs782525; dashed green line – conditioned on rs7872525) with fibroid 
number (single vs multiple) as the outcome. The admixture mapping analysis was adjusted for 
age, BMI, five PCs. The solid green line represents the significance threshold. The solid blue line 
represents the suggestive threshold. The bottom portion of the Y-axis indicates the log10(p value) 
for the single SNP association analyses (blue circles indicates genotyped SNPs; red circles 
indicates imputed SNPs) with fibroid number (single vs multiple) as the outcome. The imputed 
region was found by taking 1 –log down from the most significant mapping peak above the 
suggest threshold. The imputed region encompassed 129,822,797 to 134,670,462 bp. The single 
SNP association analysis was adjusted for age, BMI, and five PCs. The SNP, rs782525, was 
imputed (BioVU info score – 0.999; CARDIA info score – 0.985). The dotted red line represents 
the significance threshold.  
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Appendix GG. Admixture mapping for number of fibroids in African American women in candidate regions that have been 
implicated in prior studies. 
Number 
e 
12q14.1-q14.3 
Nearby Gene Cohort OR [95% CI]
 a 
p
 a
 OR [95% CI]
 b
 p
 b
 OR [95% CI]
 c
 p
 c
 OR [95% CI]
 d
 p
 d
 
HMGA2 
BioVU 1.45 [0.98, 2.17] 0.066 1.25 [0.82, 1.90] 0.294 1.25 [0.82, 1.90] 0.294 1.02 [0.65, 1.60] 0.941 
CARDIA 3.58 [1.36, 9.42] 9.60x10
-3
 2.11 [0.77, 5.79] 0.149 2.62 [0.92, 7.41] 0.070 1.26 [0.39, 4.06] 0.694 
Meta-analysis 1.66 [1.15, 2.40] 7.21x10
-3
 1.35 [0.92, 1.99] 0.128 1.39 [0.94, 2.05] 0.099 1.05 [0.69, 1.59] 0.834 
a Model 1: Adjusted for age, BMI, and 5 PCs; 
b Model 2: Adjusted for age, BMI, and 5 PCs + adjustment for most significant single SNP; 
c Model 3: Adjusted for age, BMI, and 5 PCs + adjustment for second most significant single SNP; 
d Model 4: Adjusted for age, BMI, and 5 PCs + adjustment for most and second most significant single SNP; 
e Number is coded as single vs multiple fibroids; 
CI-confidence interval; p-p-value. 
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Appendix HH. Single SNP signals in admixture mapping regions for number of fibroids in African American women in 
candidate regions that have been implicated in prior studies. 
Number
 b 
rs2575289 in 12q14.1-q14.3 
Cohort OR [95% CI]
 a
 p EA/RA BioVU/CARDIA EAF 
BioVU 0.49 [0.16, 0.82] 3.63x10
-3
 A/G 0.24/0.26 
CARDIA 1.13 [0.50, 1.73] 4.05x10
-4
   
Meta-analysis 0.63 [0.34, 0.92] 2.29x10
-5
   
rs56133667 in 12q14.1-q14.3 
Cohort OR [95% CI]
 a
 p EA/RA BioVU/CARDIA EAF 
BioVU 1.32 [0.36, 2.28] 7.30x10
-3
 T/G 0.08/0.05 
CARDIA 0.98 [0.33, 1.64] 3.29x10
-3
   
Meta-analysis 1.09 [0.55, 1.63] 8.19x10
-5
   
a Model 1: Adjusted for age, BMI, and 5 PCs; 
b Number is coded as single vs multiple fibroids; 
CI-confidence interval; p-p-value; EA-effect allele; RA-reference allele; EAF-effect allele frequency. 
 
 
106 
 
 
 
Appendix II. Admixture mapping analysis of chromosome 12 with overlapping single SNP 
association analysis results. 
The X-axis indicates the genomic position along chromosome 10 in Mb. The top of the Y-axis 
indicates -log10(p value) from the meta-analysis between BioVU and CARDIA AA from logistic 
regression of admixture mapping values that were generated from LAMP-ANC (solid black line 
– not conditioned for rs2575289 or rs56133667; dashed teal line – conditioned on rs2575289; 
dashed yellow line - conditioned on rs56133667; dashed purple line - conditioned on rs2575289 
and rs56133667) with fibroid number (single vs multiple) as the outcome. The admixture 
mapping analysis was adjusted for age, BMI, five PCs. The solid green line represents the 
significance threshold. The solid blue line represents the suggestive threshold. The bottom 
portion of the Y-axis indicates the log10(p value) for the single SNP association analyses (blue 
circles indicates genotyped SNPs; red circles indicates imputed SNPs) with fibroid number 
(single vs multiple) as the outcome. The imputed region was found by taking 1 –log down from 
the most significant mapping peak above the suggest threshold. The imputed region 
encompassed 61,300,873 to 67,610,913 bp. The single SNP association analysis was adjusted for 
age, BMI, and five PCs. The SNP, rs2575289, was imputed (BioVU info score – 0.976; 
CARDIA info score – 0.991). The SNP, rs56133667, was imputed (BioVU info score > 0.999; 
CARDIA info score > 0.999).  The dotted red line represents the significance threshold of the 
single SNP association analysis.  
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